

## Author Index for 1994

Ackenheil, M. 53:77, 53:203  
Acuña-Castroviejo, D. 52:273  
Adams, D. 54:241  
Ainsworth, B. 52:199  
Al-Shabbout, M. 51:269  
Aldenhoff, J.B. 51:253  
Alevizos, B. 52:259  
Aliyev, N.N. 54:307  
Allen, E.M. 51:283  
Alliger, R.J. 53:243  
Allilaire, J.-F. 52:85  
Alpert, M. 54:211  
Alphs, L.D. 52:173, 54:71  
Alroy, D. 53:1  
Altshuler, L.L. 51:283  
Amaro, S. 53:185  
Andersen, H.S. 53:57  
Andersen, J.S. 52:327  
Andreasen, N.C. 53:243, 54:25  
Andreasen, P.J. 51:175  
Ansseau, M. 52:115  
Arancio, C. 52:159  
Arbisi, P.A. 52:199  
Arida, J. 52:25  
Arndt, S.V. 54:25  
Asai, K. 51:147  
Asarnow, R.F. 54:59  
Attack, J.R. 53:103  
Axelrod, B.N. 52:173  
Babron, M.C. 51:215, 52:135  
Baldwin, P. 51:175  
Balon, R. 54:97  
Barber, J.P. 53:191  
Bartko, J.J. 52:237, 52:251  
Bastard, C. 51:215, 52:135  
Battaglia, M. 52:159  
Bauer, M. 51:61, 51:75  
Baumgartner, A. 51:61, 51:75, 53:109  
Baxter, L.R., Jr. 51:283, 53:107  
Beam-Goulet, J.L. 52:295, 54:51  
Beck, A.T. 51:167  
Bell, M.D. 52:295, 54:51  
Bellodi, L. 52:159, 54:135  
Bendsen, B.B. 53:57  
Benoit, O. 52:85  
Berchou, R. 54:97  
Berger, R. 54:97  
Bernard, J. 51:107  
Bertani, A. 52:159, 54:135  
Betz, F. 51:167  
Biederman, J. 53:13  
Birmaher, B. 51:269  
Black, F.W. 54:37  
Blockx, P. 51:185  
Borcherding, B.G. 54:199  
Borges, A. 54:37  
Borrelli, D. 51:157  
Bosmans, E. 54:143  
Bossche, B.V. 54:143  
Bowers, M.B., Jr. 52:11  
Boyko, O. 54:295  
Bracha, H.S. 53:119  
Braga, M. 53:41  
Brambilla, F. 53:231, 54:135  
Brar, J.S. 51:1  
Brewerton, T.D. 52:71  
Brown, S.-L. 53:219  
Bruinvels, J. 51:11  
Bruss, G.S. 53:191  
Bryson, G.J. 52:265  
Buysse, D.J. 51:297  
Campion, D. 51:215, 52:135  
Caron, M.G. 52:17  
Cartwright, R.D. 51:245  
Casacchia, M. 52:43  
Castellanos, F.X. 52:305  
Castellon, S.A. 54:59  
Caudle, J. 52:103  
Charak, D.A. 52:25  
Charney, D.S. 54:115  
Chengappa, K.N.R. 51:1  
Cherry, L. 53:111  
Christenson, C.D. 53:119  
Clerget-Darpoux, F. 52:135  
Cohen, R.M. 51:175  
Cook, E.H., Jr. 52:25  
Core, L. 52:43  
Cornblatt, B.A. 54:259  
Cornwell, J. 54:37  
Corrigan, P.W. 53:141  
Cosyns, P. 51:185, 54:143  
Crain, B.J. 54:295  
Crowe, R.R. 54:25  
Cuesta, M.J. 53:31  
Czobor, P. 52:107  
d'Amato, T. 51:215, 52:135  
D'Hondt, P. 51:185, 54:143  
d'Istria, M. 53:185  
Dahl, R.E. 51:269  
Dai, X.Y. 52:149  
Dantchev, N. 52:85  
Darko, D.F. 52:1  
Davidson, J.R.T. 52:35  
Davis, J.M. 51:51  
Davis, K.L. 53:1  
De Luca, B. 53:185  
Denise, P. 52:85  
Dennis, B. 51:231  
Depue, R.A. 52:199  
Dettling, J. 51:297  
Di Michele, V. 52:43  
Dieci, M. 53:41  
Diehl, D.J. 54:177  
Dingemans, P.M. 54:273  
Dollfus, S. 51:215  
Doraismamy, P.M. 52:35  
Doré, C. 54:241  
Dressing, H. 51:253  
Duncan, M.A. 53:1  
Dunner, D. 52:327  
Dysken, M.W. 51:203  
Eckardt, M.J. 54:225  
Ehlers, C.L. 54:161  
Elia, J. 52:305, 54:199  
Elin, R.J. 54:199  
Ellinwood, E.H. 51:115  
Endicott, J. 53:301  
Ernst, M. 51:87  
Ertl, M.A. 53:77, 53:203  
Faraone, S.V. 53:13  
Faries, D.E. 52:327  
Fassone, G. 53:231  
Faull, K. 51:51  
Feil, K.J. 52:99  
Fekkes, D. 51:11  
Flaskerud, J.H. 53:289  
Flaum, M. 53:243, 54:25  
Franc, B. 52:85  
Frank, E. 51:33, 51:297, 52:55  
Franke, P. 54:259  
Freedman, R. 52:237, 52:251  
Friberg, L. 53:57  
Friedman, A.H. 54:295  
Fukuda, R. 52:149  
Gallucci, M. 52:43  
Gamache, P.H. 52:237  
Ganguli, R. 51:1  
Gann, H. 51:253  
Garbarini, M. 53:41  
Garberi, A. 52:159  
Gardner, D.M. 52:327  
George, C.J. 51:33  
George, M.S. 51:139

Gerhardt, G.A. 52:237,  
     52:251  
 Germine, M. 54:115  
 Gillen, J.S. 54:177  
 Gillin, J.C. 52:327  
 Giobbio, G.M. 53:41  
 Giros, B. 52:17  
 Glover, V. 54:241  
 Goddard, A.W. 54:115  
 Godfrey, K.A. 51:87  
 Goisman, R. 54:249  
 Goldenberg, I. 54:249  
 Goldman, R.S. 52:173  
 Goldstein, M.J. 54:59  
 Goldstein, R.D. 53:191  
 Gorwood, P. 51:215, 52:135  
 Gottesman, I.I. 52:125  
 Gräf, K.-J. 51:61,  
     51:75  
 Green, M.F. 53:119, 53:141  
 Greenfeld, D.G. 52:11  
 Griffin, M. 51:157  
 Grochocinski, V.J. 54:161  
 Grossman, I. 51:231  
 Grove, W.M. 52:99  
 Gruenberg, A.M. 53:191  
 Gubbi, A.V. 51:1  
 Guedj, F. 51:215  
 Gullion, C.M. 52:55  
 Gulotta, C.S. 52:305  
 Guo, A.C. 51:175  
 Gur, R.C. 51:19, 52:215  
 Gur, R.E. 51:19, 52:215  
 Gurklis, J. 54:13  
 Guze, B.H. 51:283  
 Haas, G.L. 54:185  
 Haden, C. 52:103  
 Hain, C. 54:259  
 Hallmayer, J. 53:77,  
     53:203  
 Hamburger, S. 54:199  
 Hansen, M. 52:115  
 Hardin, T.A. 52:71  
 Hardt, J. 54:259  
 Harrow, M. 52:265  
 Harvey, P.D. 53:1,  
     54:211  
 Hattori, M. 52:149  
 Hatzimanolis, J. 52:259  
 Heiligenstein, J.H.  
     52:327  
 Hemmingsen, R. 53:57  
 Heninger, G.R. 54:115  
 Hill, J.L. 52:181  
 Holm, S. 53:57  
 Hoover, K.M. 51:203  
 Hosseini, J.M. 54:199  
 Houck, P.R. 51:33  
 Hu, L. 53:289  
 Iacono, W.G. 52:99  
 Invernizzi, G. 53:41  
 Irwin, M. 52:1  
 Issa, F. 52:237, 52:251  
 Iwata, N. 53:275  
 Jacobsen, F.M. 52:181  
 Jaggi, J.L. 52:215  
 James, S.P. 52:327  
 Janicak, P.G. 51:51  
 Javaid, J.I. 51:51  
 Jay, M. 51:215, 52:135  
 Joffe, R.T. 53:313  
 Johnson, J. 54:37  
 Johnson, K. 51:115  
 Jordan, S. 52:285  
 Joyce, E.M. 54:225  
 Kalin, N.H. 52:103  
 Kanal, E. 54:177  
 Kanba, S. 52:149  
 Kato, T. 52:149  
 Kaufman, A. 51:231  
 Kazamatsuri, H. 52:149  
 Keefe, R.S.E. 53:1  
 Keller, M. 54:249  
 Kandler, K.S. 52:125  
 Keshavan, M.S. 54:177  
 Kim, E. 53:301  
 Kim, S.W. 51:203  
 Kirch, D.G. 52:237, 52:251  
 Klemfuss, H. 53:173  
 Kling, M.A. 51:139  
 Kopp, B. 53:129  
 Kotler, M. 53:219  
 Kraemer, H.C. 52:55  
 Krahn, D.D. 52:71  
 Kramer, G. 52:285  
 Krauss, S. 52:199  
 Kring, A.M. 54:211  
 Kripke, D.F. 53:161, 53:173  
 Krishnan, K.R.R. 52:35,  
     54:283, 54:295  
 Kruesi, M.J.P. 52:305,  
     54:199  
 Kumar, A.M. 53:99  
 Kupfer, D.J. 51:33, 51:297,  
     52:55, 54:161  
 Kürten, I. 51:61, 51:75  
 Laev, H. 53:87  
 Lapey, K.A. 53:13  
 Larsen, J.K. 53:57  
 Laskowitz, D.T. 54:283  
 Lassen, N.A. 53:57  
 Laurent, C. 51:215, 52:135  
 Lahmeyer, H. 52:327  
 Lee, E.-K. 54:295  
 Lee, H.P. 54:305  
 Lee, J. 54:305  
 Lees Roitman, S.E. 53:1  
 Lenior, M.E. 54:273  
 Leon, A. 52:199  
 Leuchter, A.F. 54:1  
 Levenson, L. 51:127  
 Leventhal, B.L. 52:25  
 Levitt, A.J. 53:313  
 Lewine, R.R.J. 52:103  
 Li, S. 54:185  
 Li, T. 52:17  
 Libiger, J. 52:107  
 Lichtermann, D. 53: 77, 53:203  
 Lieb, K. 54:1  
 Lindenmayer, J.-P. 52:295  
 Linszen, D.H. 54:273  
 Liston, E.H. 51:283  
 Littlewood, J. 54:241  
 Liu, X. 52:17  
 Lloyd, S.R. 51:245  
 Loneragan, C. 54:87  
 Lynch, M. 52:237  
 Lysaker, P.H. 52:295, 54:51  
 MacLean, C.J. 52:125  
 Madsen, P.L. 53:57  
 Maes, M. 51:185, 52:317,  
     54:143  
 Mahadik, S.P. 53:87  
 Maier, W. 53:77, 53:203,  
     54:259  
 Maj, M. 53:185  
 Mallet, J. 51:215, 52:135  
 Mancini, F. 52:43  
 Marder, S.R. 54:59  
 Marini, S. 53:231  
 Markianos, M. 52:259  
 Martin, P.R. 54:225  
 Martinez, M. 51:215, 52:135  
 Massicotte, G. 51:107  
 Mathew, R.J. 51:115  
 Mattei, P. 52:43  
 Mattler, U. 53:129  
 Mazure, C.M. 52:11  
 McDermott, B.E. 54:37

McDonald, W.M. 54:283  
 McFarlin, K.E. 54:199  
 Mednitsky, S. 51:231  
 Mefford, I.N. 52:305  
 Mellman, T.A. 53:99  
 Meltzer, H.Y. 52:317, 54:71,  
     54:143  
 Mick, E. 53:13  
 Miewald, J.M. 54:161  
 Miller, E.N. 54:1  
 Milstein, R.M. 52:295,  
     54:51  
 Minges, J. 53:77, 53:203  
 Mirin, S.M. 51:157  
 Mohs, R.C. 53:1  
 Moises, H.W. 52:17  
 Molchan, S.E. 53:103  
 Molcho, A. 53:219  
 Molina-Carballo, A. 52:273  
 Monk, T.H. 51:297  
 Monteleone, P. 53:185  
 Moreno, A.G. 52:115  
 Morganti, C. 53:41  
 Morgenstern, H. 54:1  
 Mori, H. 51:147  
 Morikawa, T. 53:153  
 Mueller, E.A. 52:181  
 Muenz, L.R. 51:19  
 Muir, R. 52:199  
 Mukherjee, S. 53:87  
 Müller, W.E. 51:253  
 Muñoz-Hoyos, A. 52:273  
 Murphy, D.L. 52:181  
 Musselman, D.L. 52:103  
 Nankai, M. 51:147  
 Nanko, S. 52:149  
 Neale, J.M. 54:211  
 Nebes, R.D. 54:177  
 Nelson, B. 51:269  
 Nerozzi, D. 53:231  
 Newton, T.F. 54:1  
 Nichols, T.E. 54:177  
 Nugter, M.A. 54:273  
 O'Leary, D.S. 53:243  
 O'Neill, P. 54:37  
 Ohayon, M. 51:107  
 Okayli, G. 54:143  
 Pancheri, P. 53:231  
 Pande, A.C. 52:327  
 Panerai, A. 54:135  
 Peppinkhuizen, L. 51:11  
 Peralta, V. 53:31  
 Perel, J. 51:269, 54:161  
 Perna, G. 52:159,  
     54:135  
 Peters, J.L. 54:13  
 Petit, C. 52:135  
 Petit, M. 51:215  
 Petty, F. 52:285  
 Pheley, A.M. 51:203  
 Picardi, A. 53:231  
 Pitchot, W. 52:115  
 Plutchik, R. 53:219  
 Pohl, R. 54:97  
 Pollock, B.G. 54:161  
 Post, R.M. 51:139  
 Potter, W.Z. 52:305  
 Potts, N.L.S. 52:35  
 Pouget, E.R. 51:87  
 Price, L.H. 51:127  
 Priebe, S. 51:61, 51:75  
 Prigerson, H.G. 51:33  
 Puig-Antich, J. 51:269  
 Rabin, B.S. 51:1  
 Radtke, R.A. 54:295  
 Raoux, N. 52:85  
 Rapoport, J.L. 52:305  
 Rawlings, R.R. 54:225  
 Reddy, R.R. 53:87  
 Reich, J. 54:249  
 Resovsky, K. 52:1  
 Reynolds, C.F., III 51:33  
 Riemann, D. 51:253  
 Rio, D.E. 54:225  
 Risch, S.C. 52:103  
 Rist, F. 53:129  
 Ritchie, G.F. 52:305  
 Ritenour, A.M. 51:297  
 Roberts, R.E. 53:259,  
     53:275  
 Rodríguez-Cabezas, T.  
     52:273  
 Roffwarg, H.P. 52:327  
 Rogers, S. 52:181  
 Rohrbaugh, J.W. 54:225  
 Roizen, N.J.M. 52:25  
 Rosenstein, D. 51:139  
 Rosenthal, N.E. 52:71,  
     52:181  
 Rossi, A. 52:43  
 Roy, M.-A. 54:25  
 Rubin, P. 53:57  
 Rubinow, D.R. 51:139  
 Rush, A.J. 52:55, 52:327  
 Ruttimann, U.E. 54:225  
 Ryan, N.D. 51:269  
 Sacerdote, P. 54:135  
 Sachdev, P. 54:87  
 Saito, A. 53:231  
 Saito, K. 53:275  
 Sakado, K. 53:153  
 Samson, J.A. 51:157  
 Sanderson, W.C. 51:167  
 Santangelo, C. 53:301  
 Sasaki, T. 52:149  
 Sato, S. 53:153  
 Sato, T. 53:153  
 Satz, P. 53:119, 54:1  
 Sautter, F.J. 54:37  
 Savoye, C. 52:135  
 Scharff, L. 51:231  
 Sharpé, S. 54:143  
 Schechter, D. 53:301  
 Schildkraut, J.J. 51:157  
 Schmidt, M.E. 54:199  
 Schneider, F. 51:19, 52:215  
 Schnur, D.B. 53:87  
 Scholte, W.F. 54:273  
 Schwab, S. 53:77, 53:203  
 Schwartz, J.M. 51:283  
 Serino, I. 53:185  
 Sevy, S. 53:219  
 Sham, P.C. 52:125  
 Sharma, R.P. 51:51  
 Shedlack, K.J. 54:283, 54:295  
 Sholomskas, D.E. 54:115  
 Shuchter, S.R. 52:1  
 Shurin, G. 51:1  
 Siever, L.J. 53:1  
 Silva, R.R. 51:87  
 Silverman, J.M. 53:1  
 Silverstein, M.L. 52:265  
 Sledge, P. 52:1  
 Spencer, T. 53:13  
 Spohn, J.A. 52:25  
 Spooft, M.R. 52:199  
 Srinivasan, K. 54:97  
 Stefanis, C. 52:259  
 Strasser, T.J. 53:301  
 Stratta, P. 52:43  
 Strømsø, N. 53:57  
 Suddath, R.L. 52:237, 52:251  
 Sunderland, T. 53:103  
 Suzuki, S. 53:259  
 Swann, A.C. 53:111  
 Swayze, V.W., II 53:243

Sweeney, J.A. 54:185  
Szuba, M.P. 51:283, 53:107  
Takeuchi, K. 53:259  
Taylor, A. 54:241  
Thibaut, F. 51:215  
Thompson, P.A. 52:317  
Tietjen, G.H. 53:161  
Tollefson, G.D. 52:327  
Toomey, R. 53:141  
Toru, M. 41:147  
Van der Does, A.J.W. 54:273  
van Gorp, W.G. 54:1  
van Kammen, D.P. 54:13  
van Praag, H.M. 53:219  
Vasile, R. 54:249  
Verheij, R. 51:11  
Videbech, P. 53:57  
Visscher, B. 54:1  
Vita, A. 53:41  
Volavka, J. 52:107

von Frenckell, R. 52:115  
Vrtunski, P.B. 54:71  
Wakade, C.G. 53:87  
Waksman, G. 51:215, 52:135  
Walter, D.O. 54:1  
Warrenburg, S. 51:127  
Watanabe, A. 51:147  
Wauthy, J. 52:115  
Wehr, T.A. 52:71  
Weiden, P.J. 54:185  
Weiner, H. 54:1  
Welkowitz, J. 51:87  
Wesson, V.A. 53:313  
Westbrook, F. 54:87  
Wetzler, S. 51:167, 53:219  
Wexler, B.E. 51:127  
Widlöcher, D. 52:85  
Wiese, C. 52:17  
Wildenauer, D. 53:77, 53:203

Wilens, T. 53:13  
Wilkins, L. 54:305  
Wilson, L. 52:285  
Wilson, W.H. 51:115  
Woodard, J.L. 52:173  
Woods, S.W. 54:115  
Wyatt, R.J. 52:237, 52:251  
Xu, C.T. 52:17  
Yamada, S. 51:147  
Yang, L. 52:17  
Yang, Z. 51:1  
Yao, J.K. 54:13  
Yeragani, V.K. 54:97  
Yoshimoto, S. 51:147  
Zajecka, J. 52:327  
Zametkin, A.J. 51:175  
Zeng, Z. 52:17  
Zisook, S. 52:1

## Subject Index for 1994

### **Acquired immune deficiency syndrome**

- electroencephalography, fronto-occipital coherence, 54:1
- electroencephalography, neuropsychological performance, 54:1
- fronto-occipital coherence, electroencephalography, 54:1
- neuropsychological performance, electroencephalography, 54:1

### **Adenosine triphosphate**

- affective disorder, family members, 53:111
- affective disorder, genetics, 53:111
- affective disorder, lymphoblastoid cells, 53:111
- bipolar disorder, family members, 53:111
- genetics, affective disorder, 53:111
- lymphoblastoid cells, affective disorder, 53:111
- schizophrenia, platelet aggregation, 54:13

### **Adrenocorticotrophic hormone**

- affective disorder, cortisol, 51:185
- affective disorder, dexamethasone, 51:185
- affective disorder, melancholic subtype, 51:185
- cannabinol use, substance abuse, 52:103
- cortisol, affective disorder, 51:185
- dexamethasone, affective disorder, 51:185
- dexamethasone, melancholic subtype, 51:185
- melancholic subtype, cortisol, 51:185
- melancholic subtype, dexamethasone, 51:185
- substance abuse, cannabinol use, 52:103

### **Affective disorder**

- adenosine triphosphate, bipolar disorder, 53:111
- adenosine triphosphate, genetics, 53:111
- adenosine triphosphate, lymphoblastoid cells, 53:111
- adrenocorticotrophic hormone, melancholic subtype, 51:185
- amino acids, immune system, 54:143
- antidepressant response, circadian rhythm, 52:85
- antidepressant response, folate, 53:313
- antidepressant response, motor activity, 52:85
- antidepressant response, sleep, 52:85
- antidepressant response, symptom severity, 53:313
- antidepressant therapy, magnesium, 51:139
- antidepressant therapy, personality disorder, 53:153
- antidepressant therapy, rapid eye movement latency, 52:327
- antidepressant therapy, sleep, 52:327
- antidepressant therapy, treatment response prediction, 52:327
- anxiety symptoms, biogenic amines, 52:259

### **Affective disorder continued**

- arecoline, childhood depression, 51:269
- arecoline, gender differences, 51:269
- arecoline, growth hormone, 51:269
- arecoline, hypothalamic-pituitary-adrenal axis, 51:269
- bereavement, immune function, 52:1
- bereavement, lymphocyte counts, 52:1
- bereavement, natural killer cells, 52:1
- bereavement, T-cells, 52:1
- biogenic amines, anxiety symptoms, 52:259
- biogenic amines in plasma, moclobemide, 52:259
- biogenic amines in plasma, monoamine oxidase inhibitors, 52:259
- biogenic amines in plasma, treatment response, 52:259
- bipolar disorder, adenosine triphosphate, 53:111
- bipolar disorder, family members, 53:111
- bipolar disorder, carbamazepine, 51:139
- bipolar disorder, genetics, 53:111
- bipolar disorder, lymphoblastoid cells, 53:111
- bipolar disorder, magnesium, 51:139
- carbamazepine, bipolar subtype, 51:139
- carbamazepine, magnesium, 51:139
- childhood depression, arecoline, 51:269
- childhood depression, hypothalamic-pituitary-adrenal axis, 51:269
- children, pictorial instrument for mood assessment, 51:87
- circadian rhythm, antidepressant response, 52:85
- circadian rhythm, imipramine, 51:297
- circadian rhythm, motor activity, 52:85
- circadian rhythm, psychotherapy response, 51:297
- circadian rhythm, sleep, 52:85
- circadian rhythm, temperature, 51:297
- circadian temperature rhythm, fluoxetine, 51:297
- circadian temperature rhythm, sleep, 51:297
- circannual rhythm, suicide, 53:161
- circannual rhythm, sunshine hours, 53:161
- circannual rhythm, weather, 53:161
- client-therapist ethnic match, treatment outcome, 53:289
- clomipramine, rapid eye movement rebound, 54:161
- clomipramine, sleep, 54:161
- clonidine response, growth hormone, 52:115
- clonidine response, suicide attempts, 52:115
- cortisol, adrenocorticotrophic hormone, 51:185
- cortisol, dexamethasone, 51:185
- cortisol, East German refugees, 51:75
- cortisol, melancholic subtype, 51:185
- delayed vs. immediate recall, intelligence, 51:231

**Affective disorder** continued

delayed vs. immediate recall, neuropsychology, 51:231

depression symptoms, dream reports, 51:245

depression symptoms, rapid eye movement latency, 51:245

depression symptoms, sleep, 51:245

depressive symptoms, Japanese and American adolescents, 53:259

desmethylimipramine, lithium, 51:283

desmethylimipramine, sleep deprivation, 51:283

desmethylimipramine, treatment response, 51:283

dexamethasone, adrenocorticotrophic hormone, 51:185

dexamethasone, cortisol, 51:185

dexamethasone, gender, 51:185

dexamethasone, melancholic subtype, 51:185

dexamethasone, thyroxine, 51:185

dexamethasone, triiodothyronine, 51:185

dopamine D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub> receptor gene loci, 52:149

dopamine, genetics, 52:149

dopamine, linkage analysis, 52:149

dream reports, depression symptoms, 51:245

dream reports, rapid eye movement latency, 51:245

dream reports, sleep, 51:245

electroconvulsive therapy, magnetic resonance imaging, 54:177

electroconvulsive therapy, memory, 54:177

electroconvulsive therapy, thalamus, 54:177

electromyography, facial expression, 51:127

electromyography, positive vs. neutral words, 51:127

facial expression, electromyography, 51:127

facial expression, positive vs. neutral words, 51:127

family members, adenosine triphosphate, 53:111

family members, bipolar disorder, 53:111

family members, lymphoblastoid cells, 53:111

fluoxetine, circadian temperature rhythm, 51:297

fluoxetine, rapid eye movement latency, 52:327

fluoxetine, sleep, 51:297, 52:327

fluoxetine, treatment response prediction, 52:327

folate, antidepressant response, 53:313

folate, symptom severity, 53:313

gender, dexamethasone, 51:185

gender differences, arecoline, 51:269

genetics, adenosine triphosphate, 53:111

genetics, bipolar disorder, 53:111

genetics, dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, 52:149

genetics, linkage analysis, 52:149

genetics, lymphoblastoid cells, 53:111

growth hormone, arecoline, 51:269

growth hormone, clonidine response, 52:115

**Affective disorder** continued

growth hormone, suicide attempts, 52:115

homovanillic acid, moclobemide treatment response, 52:259

5-hydroxyindoleacetic acid, moclobemide treatment response, 52:259

hypothalamic-pituitary-adrenal axis, arecoline, 51:269

hypothalamic-pituitary-adrenal axis, childhood depression, 51:269

imipramine, circadian rhythms, 51:297

imipramine, psychotherapy response, 51:297

imipramine, temperature, 51:297

immune function, bereavement, 52:1

immune function, lymphocyte counts, 52:1

immune function, natural killer cells, 52:1

immune function, T-cells, 52:1

immune system, amino acids, 54:143

intelligence, delayed vs. immediate recall, 51:231

intelligence, memory, 51:231

intelligence, neuropsychology, 51:231

interferon secretion, neopterin, 54:143

interferon secretion, tryptophan, 54:143

Japanese and American adolescents, depressive symptoms, 53:259

linkage analysis, dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, 52:149

lithium, desipramine, 51:283

lithium, magnesium, 51:139

lithium, sleep deprivation, 51:283

lithium treatment, 3-methoxy-4-hydroxyphenyl-etheneglycol, 51:51

lithium, treatment response, 51:283

luteinizing hormone, East German refugees, 51:75

luteinizing hormone, posttraumatic stress disorder, 51:75

lymphoblastoid cells, adenosine triphosphate, 53:111

lymphoblastoid cells, bipolar disorder, 53:111

lymphoblastoid cells, family members, 53:111

lymphoblastoid cells, genetics, 53:111

lymphocyte counts, bereavement, 52:1

lymphocyte counts, immune function, 52:1

lymphocyte counts, natural killer cells, 52:1

lymphocyte counts, T-cells, 52:1

magnesium, antidepressant treatment, 51:139

magnesium, bipolar subtype, 51:139

magnesium, carbamazepine, 51:139

magnesium, lithium, 51:139

magnetic resonance imaging, electroconvulsive therapy, 54:177

magnetic resonance imaging, memory, 54:177

magnetic resonance imaging, thalamus, 54:177

**Affective disorder** continued

melancholic subtype, adrenocorticotrophic hormone, 51:185  
 melancholic subtype, cortisol, 51:185  
 melancholic subtype, dexamethasone, 51:185  
 melancholic subtype, thyroid stimulating hormone, 51:185  
 memory, delayed vs. immediate recall, 51:231  
 memory, electroconvulsive therapy, 54:177  
 memory, intelligence, 51:231  
 memory, thalamus, 54:177  
 meta-chlorophenylpiperazine response, phototherapy, 52:181  
 meta-chlorophenylpiperazine response, seasonal affective disorder, 52:181  
 methionine, plasma levels, 51:11  
 methionine, serine, 51:11  
 methionine, taurine, 51:11  
 3-methoxy-4-hydroxyphenylethleneglycol, antidepressants, 51:51  
 3-methoxy-4-hydroxyphenylethleneglycol, lithium treatment, 51:51  
 3-methoxy-4-hydroxyphenylethleneglycol, moclobemide treatment response, 52:259  
 3-methoxy-4-hydroxyphenylethleneglycol, sleep, 51:157  
 3-methoxy-4-hydroxyphenylethleneglycol, unipolar subtype, 51:157  
 moclobemide, biogenic amines in plasma, 52:259  
 moclobemide, monoamine oxidase inhibitors, 52:259  
 moclobemide, treatment response, 52:259  
 moclobemide, treatment response, homovanillic acid, 52:259  
 moclobemide, treatment response, 5-hydroxy-indoleacetic acid, 52:259  
 monoamine oxidase inhibitors, biogenic amines in plasma, 52:259  
 monoamine oxidase inhibitors, moclobemide, 52:259  
 monoamine oxidase inhibitors, treatment response, 52:259  
 motor activity, antidepressant response, 52:85  
 motor activity, circadian rhythm, 52:85  
 motor activity, sleep, 52:85  
 natural killer cells, bereavement, 52:1  
 natural killer cells, immune function, 52:1  
 natural killer cells, lymphocyte counts, 52:1  
 natural killer cells, T-cells, 52:1  
 neopterin, interferon secretion, 54:143  
 neopterin, tryptophan, 54:143  
 neuropsychology, intelligence, 51:231

**Affective disorder** continued

neuropsychology, memory, 51:231  
 paroxetine binding, antidepressants, 51:147  
 paroxetine binding, platelets, 51:147  
 paroxetine binding, serotonin, 51:147  
 personality disorder, antidepressant therapy, 53:153  
 personality disorder, treatment response, 53:153  
 phototherapy, meta-chlorophenylpiperazine, 52:181  
 phototherapy, seasonal affective disorder, 52:181  
 posttraumatic stress disorder, East German refugees, 51:61, 51:75  
 posttraumatic stress disorder, luteinizing hormone, 51:75  
 posttraumatic stress disorder, testosterone, 51:75  
 posttraumatic stress disorder, triiodothyronine, 51:61  
 prolactin, posttraumatic stress disorder, 51:75  
 psychotherapy, client-therapist ethnic match, 53:289  
 psychotherapy response, circadian rhythms, 51:297  
 psychotherapy response, temperature, 51:297  
 psychotherapy, treatment outcome, 53:289  
 rapid eye movement, antidepressants, 52:327  
 rapid eye movement latency, depression symptoms, 51:245  
 rapid eye movement latency, dream reports, 51:245  
 rapid eye movement latency, fluoxetine, 52:327  
 rapid eye movement latency, treatment response prediction, 52:327  
 rapid eye movement rebound, clomipramine, 54:161  
 rapid eye movement rebound, desmethyl-clomipramine metabolite, 54:161  
 rapid eye movement rebound, sleep, 54:161  
 seasonal affective disorder, meta-chlorophenylpiperazine, 52:181  
 seasonal affective disorder, phototherapy, 52:181  
 serine, methionine, 51:11  
 serine, plasma levels, 51:11  
 serine, taurine, 51:11  
 serotonin, antidepressants, 51:147  
 serotonin, paroxetine binding, 51:147  
 serotonin, platelets, 51:147  
 sleep, antidepressants, 52:85, 52:327  
 sleep, childhood depression, 51:269  
 sleep, circadian rhythm, 52:85  
 sleep, circadian temperature rhythm, 51:297  
 sleep, clomipramine, 54:161  
 sleep, depression symptoms, 51:245  
 sleep, desmethylclomipramine metabolite, 54:161  
 sleep, dream reports, 51:245

**Affective disorder** continued

- sleep, fluoxetine, 51:297, 52:327
- sleep, 3-methoxy-4-hydroxyphenylethylene glycol, 51:157
- sleep, motor activity, 52:85
- sleep, rapid eye movement latency, 51:245, 51:269, 52:327, 54:161
- sleep, treatment response prediction, 52:327
- sleep, unipolar subtype, 51:157
- sleep deprivation, desmethylimipramine, 51:283
- sleep deprivation, lithium, 51:283
- sleep deprivation, thyroid hormones, 53:107
- sleep deprivation, treatment response, 51:283
- suicide attempts, clonidine response, 52:115
- suicide attempts, growth hormone, 52:115
- suicide, circannual rhythm, 53:161
- suicide, sunshine hours, 53:161
- suicide, weather, 53:161
- symptom severity, antidepressant response, 53:313
- symptom severity, folate, 53:313
- T-cells, bereavement, 52:1
- T-cells, immune function, 52:1
- T-cells, lymphocyte counts, 52:1
- T-cells, natural killer cells, 52:1
- taurine, methionine, 51:11
- taurine, plasma levels, 51:11
- taurine, serine, 51:11
- temperature, circadian rhythms, 51:297
- temperature, imipramine, 51:297
- temperature, psychotherapy response, 51:297
- testosterone, posttraumatic stress disorder, 51:75
- thalamus, electroconvulsive therapy, 54:177
- thalamus, magnetic resonance imaging, 54:177
- thalamus, memory, 54:177
- thyroid hormones, sleep deprivation, 53:107
- thyroxine, dexamethasone, 51:185
- treatment outcome, antidepressants, 53:289
- treatment outcome, client-therapist ethnic match, 53:289
- treatment outcome, psychotherapy, 53:289
- treatment response, antidepressant therapy, 53:153
- treatment response, biogenic amines in plasma, 52:259
- treatment response, desmethylimipramine, 51:283
- treatment response, lithium, 51:283
- treatment response, moclobemide, 52:259
- treatment response, monoamine oxidase inhibitors, 52:259
- treatment response, personality disorder, 53:153
- treatment response prediction, antidepressants, 52:327
- treatment response prediction, fluoxetine, 52:327

**Affective disorder** continued

- treatment response prediction, rapid eye movement latency, 52:327
- treatment response prediction, sleep, 52:327
- treatment response, sleep deprivation, 51:283
- triiodothyronine, dexamethasone, 51:185
- triiodothyronine, posttraumatic stress disorder, 51:61
- tryptophan, interferon secretion, 54:143
- tryptophan, neopterin, 54:143
- thyroid stimulating hormone, melancholic subtype, 51:185
- unipolar subtype, 3-methoxy-4-hydroxyphenylethylene glycol, 51:157
- unipolar subtype, sleep, 51:157
- weather, circannual rhythm, 53:161
- weather, suicide, 53:161
- weather, sunshine hours, 53:161

**Age**

- bereavement, circadian rhythm, 51:33
- bereavement, depressive symptoms, 51:33
- bereavement, life events, 51:33
- circadian rhythm, bereavement, 51:33
- circadian rhythm, depressive symptoms, 51:33
- circadian rhythm, life events, 51:33
- circadian rhythm, mood, 51:33
- depressive symptoms, bereavement, 51:33
- depressive symptoms, circadian rhythm, 51:33
- depressive symptoms, life events, 51:33
- eating disorder, seasonal affective disorder, 52:71
- geriatric patients, magnetic resonance imaging, 54:283
- geriatric patients, periventricular signal hyperintensity, 54:283
- geriatric patients, visual hallucinations, 54:283
- interleukin, duration of illness, 51:1
- interleukin, neuroleptics, 51:1
- interleukin, schizophrenia, 51:1
- life events, bereavement, 51:33
- life events, circadian rhythm, 51:33
- life events, depressive symptoms, 51:33
- life events, mood, 51:33
- magnetic resonance imaging, putamen size, 52:35
- magnetic resonance imaging, social phobia, 52:35
- magnetic resonance imaging, geriatric patients, 54:283
- magnetic resonance imaging, periventricular signal hyperintensity, 54:283
- magnetic resonance imaging, visual hallucinations, 54:283
- mood, bereavement, 51:33
- mood, circadian rhythm, 51:33
- mood, life events, 51:33

**Age** continued

- periventricular signal hyperintensity, geriatric patients, 54:283
- periventricular signal hyperintensity, magnetic resonance imaging, 54:283
- periventricular signal hyperintensity, visual hallucinations, 54:283
- putamen size, magnetic resonance imaging, 52:35
- putamen size, social phobia, 52:35
- schizophrenia, duration of illness, 51:1
- schizophrenia, interleukin, 51:1
- schizophrenia, neuroleptics, 51:1
- seasonal affective disorder, eating disorder, 52:71
- social phobia, magnetic resonance imaging, 52:35
- social phobia, putamen size, 52:35
- visual hallucinations, geriatric patients, 54:283
- visual hallucinations, magnetic resonance imaging, 54:283
- visual hallucinations, periventricular signal hyperintensity, 54:283

**Aggression**

- attention deficit disorder, cerebrospinal fluid, 52:305
- attention deficit disorder, homovanillic acid, 52:305
- attention deficit disorder, 3-methoxy-4-hydroxyphenylethleneglycol, 52:305
- homovanillic acid, attention deficit disorder, 52:305
- 3-methoxy-4-hydroxyphenylethleneglycol, attention deficit disorder, 52:305
- 3-methoxy-4-hydroxyphenylethleneglycol, cerebrospinal fluid, 52:305

**Alcohol**

- eye movements, smooth pursuit, 52:99
- smooth pursuit, eye movements, 52:99

**Alcoholism**

- cingulate gyrus, electroencephalography, 54:225
- cingulate gyrus, Korsakoff's syndrome, 54:225
- cingulate gyrus, positron emission tomography, 54:225
- electroencephalography, Korsakoff's syndrome, 54:225
- eye movements, smooth pursuit, 52:99
- interferon, treatment effects, 307
- Korsakoff's syndrome, cingulate gyrus, 54:225
- Korsakoff's syndrome, electroencephalography, 54:225
- Korsakoff's syndrome, positron emission tomography, 54:225
- positron emission tomography, cingulate gyrus, 54:225
- positron emission tomography, Korsakoff's syndrome, 54:225
- smooth pursuit, eye movements, 52:99

**Alprazolam**

- anxiety symptoms, growth hormone, 53:219
- anxiety symptoms, meta-chlorophenylpiperazine, 53:219
- growth hormone, anxiety symptoms, 53:219
- growth hormone, meta-chlorophenylpiperazine, 53:219
- interleukin-1, panic disorder, 54:135
- meta-chlorophenylpiperazine, anxiety symptoms, 53:219
- meta-chlorophenylpiperazine, growth hormone, 53:219
- panic disorder, interleukin-1, 54:135
- panic disorder, symptom severity, 54:135

**Amino acids**

- affective disorder, immune system, 54:143
- affective disorder, tryptophan, 54:143
- immune system, affective disorder, 54:143
- neopterin, affective disorder, 54:143
- schizophrenia, psychotic symptoms, 51:11
- tryptophan, affective disorder, 54:143

***α*-Amino-3-methyl-isoxazole-4-propionate**

- antidepressant treatment, hippocampus, 51:107
- hippocampus, phospholipase A2, 51:107
- phospholipase A2, rat, 51:107
- trimipramine, phospholipase A2, 51:107

**Amphetamine**

- attention deficit disorder, calcium in plasma, 54:199
- attention deficit disorder, magnesium, 54:199
- attention deficit disorder, symptom response, 54:199
- calcium in plasma, attention deficit disorder, 54:199
- calcium in plasma, symptom response, 54:199
- magnesium, attention deficit disorder, 54:199
- magnesium, calcium in plasma, 54:199
- magnesium, symptom response, 54:199

**Amygdala**

- magnetic resonance imaging, schizophrenia, 52:43

**Anorexia nervosa. See** *Eating disorders***Antidepressants**

- affective disorder, circadian temperature rhythm, 51:297
- affective disorder, fluoxetine, 52:327
- affective disorder, folate, 53:313
- affective disorder, lithium, 51:139
- affective disorder, magnesium, 51:139
- affective disorder, 3-methoxy-4-hydroxyphenylethleneglycol, 51:51

**Antidepressants** continued

affective disorder, personality disorder, 53:153  
 affective disorder, rapid eye movement latency, 52:327  
 affective disorder, sleep, 51:297, 52:327  
 affective disorder, symptom severity, 53:313  
 affective disorder, treatment outcome, 53:153, 53:289  
 affective disorder, treatment response prediction, 52:327  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, hippocampus, 51:107  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, phospholipase A2, 51:107  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, rat, 51:107  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, trimipramine, 51:107  
 circadian rhythms, hamster, 53:173  
 circadian rhythms, mood, 52:85  
 circadian rhythms, motor activity, 52:85  
 circadian rhythms, treatment outcome, 52:85  
 circadian temperature rhythm, affective disorder, 51:297  
 circadian temperature rhythm, sleep, 51:297  
 fluoxetine, affective disorder, 52:327  
 fluoxetine, rapid eye movement latency, 52:327  
 fluoxetine, sleep, 52:327  
 fluoxetine, treatment response prediction, 52:327  
 folate, affective disorder, 53:313  
 folate, symptom severity, 53:313  
 hamster, circadian rhythms, 53:173  
 hippocampus, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 hippocampus, phospholipase A2, 51:107  
 hippocampus, rat, 51:107  
 hippocampus, trimipramine, 51:107  
 lithium, affective disorder, 51:139  
 lithium, magnesium, 51:139  
 lithium, sleep deprivation, 51:283  
 magnesium, affective disorder, 51:139  
 magnesium, lithium, 51:139  
 3-methoxy-4-hydroxyphenylethylene glycol, affective disorder, 51:51  
 mood, circadian rhythms, 52:85  
 mood, motor activity, 52:85  
 mood, treatment outcome, 52:85  
 motor activity, circadian rhythms, 52:85  
 motor activity, mood, 52:85  
 motor activity, treatment outcome, 52:85  
 paroxetine binding, affective disorder, 51:147

**Antidepressants** continued

paroxetine binding, bipolar subtype, 51:147  
 paroxetine binding, platelets, 51:147  
 paroxetine binding, serotonin, 51:147  
 personality disorder, affective disorder, 53:153  
 personality disorder, treatment response, 53:153  
 phospholipase A2, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 phospholipase A2, hippocampus, 51:107  
 phospholipase A2, rat, 51:107  
 phospholipase A2, trimipramine, 51:107  
 rapid eye movement latency, affective disorder, 52:327  
 rapid eye movement latency, fluoxetine, 52:327  
 rapid eye movement latency, treatment response prediction, 52:327  
 serotonin, affective disorder, 51:147  
 serotonin, bipolar subtype, 51:147  
 serotonin, paroxetine binding, 51:147  
 serotonin, platelets, 51:147  
 sleep, affective disorder, 51:297, 52:327  
 sleep, circadian temperature rhythm, 51:297  
 sleep deprivation, lithium, 51:283  
 sleep, fluoxetine, 52:327  
 sleep, rapid eye movement latency, 52:327  
 sleep, treatment response prediction, 52:327  
 symptom severity, affective disorder, 53:313  
 symptom severity, folate, 53:313  
 treatment outcome, affective disorder, 53:289  
 treatment outcome, circadian rhythms, 52:85  
 treatment outcome, mood, 52:85  
 treatment outcome, motor activity, 52:85  
 treatment response, affective disorder, 53:153  
 treatment response, personality disorder, 53:153  
 treatment response prediction, affective disorder, 52:327  
 treatment response prediction, fluoxetine, 52:327  
 treatment response prediction, rapid eye movement latency, 52:327  
 treatment response prediction, sleep, 52:327  
 trimipramine, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 trimipramine, hippocampus, 51:107  
 trimipramine, phospholipase A2, 51:107  
 trimipramine, rat, 51:107

**Anxiety disorders**

obsessive-compulsive disorder, personality disorder, 51:167  
 obsessive-compulsive disorder, social phobia, 51:167  
 personality disorder, obsessive-compulsive disorder, 51:167

**Anxiety disorders** continued

personality disorder, social phobia, 51:167  
 social phobia, obsessive-compulsive disorder, 51:167  
 social phobia, personality disorder, 51:167

**Apomorphine**

growth hormone, positive symptoms, 53:231  
 growth hormone, schizophrenia, 53:231  
 positive symptoms, growth hormone, 53:231  
 positive symptoms, prolactin, 53:231  
 positive symptoms, schizophrenia, 53:231  
 prolactin, positive symptoms, 53:231  
 prolactin, schizophrenia, 52:317, 53:231  
 schizophrenia, growth hormone, 53:231  
 schizophrenia, positive symptoms, 53:231  
 schizophrenia, prolactin, 52:317, 53:231

**Arachidonic acid**

collagen, schizophrenia, 54:13

**Arecoline**

affective disorder, childhood, 51:269  
 affective disorder, gender differences, 51:269  
 affective disorder, growth hormone, 51:269  
 affective disorder, hypothalamic-pituitary-adrenal axis, 51:269  
 blood pressure, cholinergic system, 51:269  
 blood pressure, rapid eye movement latency, 51:269  
 childhood, affective disorder, 51:269  
 childhood depression, hypothalamic-pituitary-adrenal axis, 51:269  
 cholinergic system, blood pressure, 51:269  
 cholinergic system, heart rate, 51:269  
 cholinergic system, rapid eye movement latency, 51:269  
 gender differences, affective disorder, 51:269  
 growth hormone, affective disorder, 51:269  
 heart rate, cholinergic system, 51:269  
 heart rate, rapid eye movement latency, 51:269  
 hypothalamic-pituitary-adrenal axis, affective disorder, 51:269  
 hypothalamic-pituitary-adrenals, childhood depression, 51:269  
 rapid eye movement latency, blood pressure, 51:269  
 rapid eye movement latency, cholinergic system, 51:269  
 rapid eye movement latency, heart rate, 51:269

**Ascorbic acid**

schizophrenia, cerebrospinal fluid, 52:237

**Attention**

continuous performance test, dermatoglyphics, 53:119  
 continuous performance test, minor physical anomalies, 53:119  
 continuous performance test, schizophrenia, 53:119  
 continuous performance test, second trimester development, 53:119  
 continuous performance test, siblings of schizophrenics, 259  
 dermatoglyphics, continuous performance test, 53:119  
 dermatoglyphics, minor physical anomalies, 53:119  
 dermatoglyphics, schizophrenia, 53:119  
 dermatoglyphics, second trimester development, 53:119  
 dichotic listening, electromyography, 51:127  
 dichotic listening, mood, 51:127  
 electromyography, dichotic listening, 51:127  
 electromyography, facial expression, 51:127  
 electromyography, mood, 51:127  
 facial expression, electromyography, 51:127  
 facial expression, mood, 51:127  
 genetics, continuous performance test, 259  
 genetics, siblings of schizophrenics, 259  
 memory, schizophrenia, 53:141  
 memory, social cue perception, 53:141  
 memory, social skills training, 53:141  
 minor physical anomalies, continuous performance test, 53:119  
 minor physical anomalies, dermatoglyphics, 53:119  
 minor physical anomalies, schizophrenia, 53:119  
 minor physical anomalies, second trimester development, 53:119  
 mood, dichotic listening, 51:127  
 mood, electromyography, 51:127  
 negative symptoms, one-year outcome, 54:59  
 negative symptoms, schizophrenia, 54:59  
 neuroleptic treatment, smooth pursuit eye movements, 54:185  
 schizophrenia, continuous performance test, 53:119  
 schizophrenia, dermatoglyphics, 53:119  
 schizophrenia, memory, 53:141  
 schizophrenia, minor physical anomalies, 53:119  
 schizophrenia, negative symptoms, 54:59  
 schizophrenia, one-year outcome, 54:59  
 schizophrenia, second trimester development, 53:119  
 schizophrenia, social cue perception, 53:141

**Attention** continued

- schizophrenia, social skills training, 53:141
- schizophrenia, symptom severity, 53:129
- schizophrenia, visual distractibility, 53:129
- second trimester development, continuous performance test, 53:119
- second trimester development, dermatoglyphics, 53:119
- second trimester development, minor physical anomalies, 53:119
- second trimester development, schizophrenia, 53:119
- siblings of schizophrenics, continuous performance test, 54:259
- smooth pursuit eye movements, neuroleptic treatment, 54:185
- smooth pursuit eye movements, reading letters on target, 54:185
- social cue perception, memory, 53:141
- social cue perception, schizophrenia, 53:141
- social cue perception, social skills training, 53:141
- social skills training, memory, 53:141
- social skills training, schizophrenia, 53:141
- social skills training, social cue perception, 53:141
- symptom severity, schizophrenia, 53:129
- symptom severity, visual distractibility, 53:129
- visual distractibility, schizophrenia, 53:129
- visual distractibility, symptom severity, 53:129

**Attention deficit disorder**

- aggression, homovanillic acid, 52:305
- amphetamine, calcium in plasma, 54:199
- amphetamine, magnesium, 54:199
- amphetamine, symptom response, 54:199
- calcium in plasma, amphetamine, 54:199
- calcium in plasma, magnesium, 54:199
- depressed mood, gender, 53:13
- depressed mood, sex differences, 53:13
- gender, depressed mood, 53:13
- homovanillic acid, aggression, 52:305
- 5-hydroxyindoleacetic acid, impulsivity/hyperactivity, 52:305
- impulsivity/hyperactivity, 5-hydroxyindoleacetic acid, 52:305
- intelligence, neuropsychological tests, 53:13
- magnesium, amphetamine, 54:199
- magnesium, methylphenidate, 54:199
- magnesium, red blood cells, 54:199
- magnesium, symptom response, 54:199
- 3-methoxy-4-hydroxyphenylethleneglycol, aggression, 52:305

**Attention deficit disorder** continued

- 3-methoxy-4-hydroxyphenylethleneglycol, cerebrospinal fluid, 52:305
- methylphenidate, magnesium, 54:199
- methylphenidate, red blood cells, 54:199
- neuropsychological tests, intelligence, 53:13
- red blood cells, magnesium, 54:199
- sex differences, social phobia, 53:13
- sex differences, depressed mood, 53:13
- social phobia, sex differences, 53:13
- symptom response, amphetamine, 54:199

**Autistic disorder**

- family history, family size, 52:25
- obsessive-compulsive symptoms, serotonin in plasma, 52:25

**Autoantibodies**

- schizophrenia, cytokines, 51:1

**Bereavement**

- affective disorder, immune function, 52:1
- affective disorder, lymphocyte counts, 52:1
- affective disorder, natural killer cells, 52:1
- affective disorder, T-cells, 52:1
- age, circadian rhythm, 51:33
- age, depressive symptoms, 51:33
- age, life events, 51:33
- age, mood, 51:33
- circadian rhythm, depressive symptoms, 51:33
- circadian rhythm, life events, 51:33
- circadian rhythm, mood, 51:33
- depressive symptoms, age, 51:33
- immune function, affective disorder, 52:1
- life events, depressive symptoms, 51:33
- life events, mood, 51:33
- lymphocyte counts, affective disorder, 52:1
- lymphocyte counts, immune function, 52:1
- mood, depressive symptoms, 51:33
- natural killer cells, affective disorder, 52:1
- natural killer cells, T-cells, 52:1
- T-cells, affective disorder, 52:1

**Bipolar depression.** See Affective disorder**Blood pressure**

- arecoline, cholinergic system, 51:269
- arecoline, heart rate, 51:269
- arecoline, rapid eye movement sleep latency, 51:269
- cholinergic system, arecoline, 51:269
- cholinergic system, rapid eye movement sleep latency, 51:269

**Blood pressure** continued

heart rate, arecoline, 51:269  
 heart rate, rapid eye movement latency, 51:269  
 lactate infusion, normal subjects, 54:97  
 rapid eye movement sleep latency, arecoline, 51:269

**Bulimia.** See *Eating disorders***Buspirone**

schizophrenia, prolactin response, 52:317

**Calcium**

amphetamine, attention deficit disorder, 54:199  
 attention deficit disorder, amphetamine, 54:199  
 attention deficit disorder, magnesium, 54:199  
 attention deficit disorder, symptom response, 54:199  
 magnesium, amphetamine, 54:199  
 magnesium, attention deficit disorder, 54:199

**Cannabinoids**

adrenocorticotrophic hormone, substance abuse, 52:103  
 corticotropin releasing factor, cerebrospinal fluid, 52:103  
 homovanillic acid, substance abuse, 52:103  
 5-hydroxyindoleacetic acid, substance abuse, 52:103  
 3-methoxy-4-hydroxyphenylethleneglycol, substance abuse, 52:103

**Carbamazepine**

affective disorder, bipolar subtype, 51:139  
 bipolar subtype, affective disorder, 51:139  
 magnesium, affective disorder, 51:139

**Carbon dioxide inhalation**

panic disorder, anxiety symptoms, 52:159

**Catecholamines**

schizophrenia, neuroleptic effects, 52:237

**Cerebral blood flow**

emotional discrimination task, mood, 52:215  
 frontal lobe, drug-naïve patients, 53:57  
 frontal lobe, schizophrenia, 53:57  
 laterality, mood induction task, 52:215  
 mood, emotional discrimination task, 52:215  
 mood induction task, laterality, 52:215  
 schizophrenia, drug-naïve patients, 53:57  
 schizophrenia, frontal lobe, 53:57

**Childhood disorders**

affective disorder, pictorial instrument for mood assessment, 51:87  
 affective disorder, rapid eye movement sleep latency, 51:269  
 affective disorder, sleep, 51:269  
 autistic disorder, obsessive-compulsive symptoms, 52:25  
 autistic disorder, serotonin in plasma, 52:25  
 children's response, lumbar puncture, 52:305  
 circadian rhythms, epilepsy, 52:273  
 circadian rhythms, melatonin, 52:273  
 circadian rhythms, temperature, 52:273  
 conduct disorder, pictorial instrument for psychopathology assessment, 51:87  
 conduct disorder, visual analogue scale, 51:87  
 epilepsy, circadian rhythms, 52:273  
 epilepsy, melatonin, 52:273  
 epilepsy, temperature, 52:273  
 lumbar puncture, children's response, 52:305  
 melatonin, circadian rhythms, 52:273  
 melatonin, epilepsy, 52:273  
 melatonin, temperature, 52:273  
 mood, pictorial instrument for psychopathology assessment, 51:87  
 obsessive-compulsive symptoms, autistic disorder, 52:25  
 obsessive-compulsive symptoms, serotonin in plasma, 52:25  
 pictorial instrument for mood assessment, affective disorder, 51:87  
 pictorial instrument for psychopathology assessment, conduct disorder, 51:87  
 rapid eye movement sleep latency, affective disorder, 51:269  
 serotonin in plasma, autistic disorder, 52:25  
 serotonin in plasma, obsessive-compulsive symptoms, 52:25  
 sleep, affective disorder, 51:269  
 sleep, rapid eye movement latency, 51:269  
 temperature, circadian rhythms, 52:273  
 temperature, epilepsy, 52:273  
 temperature, melatonin, 52:273  
 visual analogue scale, conduct disorder, 51:87

**Cholinergic system**  
 arecoline, blood pressure, 51:269  
 arecoline, heart rate, 51:269  
 arecoline, rapid eye movement sleep latency, 51:269  
 blood pressure, arecoline, 51:269

**Cholinergic system continued**

- blood pressure, heart rate, 51:269
- blood pressure, rapid eye movement sleep latency, 51:269
- galanthamine, cholinesterase inhibitors, 51:253
- galanthamine, rapid eye movement sleep latency, 51:253
- galanthamine, sleep, 51:253
- heart rate, arecoline, 51:269
- heart rate, rapid eye movement sleep latency, 51:269
- heart rate variability, lactate infusion, 54:97
- lactate infusion, heart rate variability, 54:97
- rapid eye movement sleep latency, arecoline, 51:269
- rapid eye movement sleep latency, blood pressure, 51:269
- rapid eye movement sleep latency, cholinesterase inhibitors, 51:253
- rapid eye movement sleep latency, galanthamine, 51:253
- rapid eye movement sleep latency, heart rate, 51:269
- sleep, cholinergic system, 51:253
- sleep, cholinesterase inhibitors, 51:253
- sleep, galanthamine, 51:253

**Cingulate gyrus**

- alcoholism, electroencephalography, 54:225
- alcoholism, positron emission tomography, 54:225
- positron emission tomography, alcoholism, 54:225
- positron emission tomography, Korsakoff's syndrome, 54:225
- electroencephalography, alcoholism, 54:225
- electroencephalography, Korsakoff's syndrome, 54:225
- Korsakoff's syndrome, positron emission tomography, 54:225

**Circadian rhythms**

- affective disorder, fluoxetine, 51:297
- affective disorder, imipramine, 51:297
- affective disorder, psychotherapy response, 51:297
- affective disorder, sleep, 51:297
- affective disorder, temperature, 51:297
- age, bereavement, 51:33
- age, depressive symptoms, 51:33
- age, life events, 51:33
- age, mood, 51:33
- antidepressants, motor activity, 52:85
- antidepressants, treatment outcome, 52:85

**Circadian rhythms continued**

- bereavement, age, 51:33
- bereavement, depressive symptoms, 51:33
- bereavement, life events, 51:33
- bereavement, mood, 51:33
- childhood disorders, epilepsy, 52:273
- childhood disorders, melatonin, 52:273
- childhood disorders, temperature, 52:273
- clorgyline, monoamine oxidase inhibitors, 53:173
- clorgyline, wheel running, 53:173
- depressive symptoms, age, 51:33
- depressive symptoms, bereavement, 51:33
- depressive symptoms, life events, 51:33
- depressive symptoms, mood, 51:33
- desmethylimipramine, hamster, 53:173
- epilepsy, childhood disorders, 52:273
- epilepsy, melatonin, 52:273
- epilepsy, temperature, 52:273
- fluoxetine, affective disorder, 51:297
- fluoxetine, sleep, 51:297
- hamster, desmethylimipramine, 53:173
- imipramine, affective disorder, 51:297
- imipramine, temperature, 51:297
- life events, bereavement, 51:33
- life events, depressive symptoms, 51:33
- life events, mood, 51:33
- melatonin, childhood disorders, 52:273
- melatonin, epilepsy, 52:273
- melatonin, temperature, 52:273
- monoamine oxidase inhibitors, clorgyline, 53:173
- mood, age, 51:33
- mood, antidepressants, 52:85
- mood, bereavement, 51:33
- mood, depressive symptoms, 51:33
- mood, life events, 51:33
- mood, motor activity, 52:85
- mood, treatment outcome, 52:85
- motor activity, antidepressants, 52:85
- motor activity, mood, 52:85
- motor activity, treatment outcome, 52:85
- psychotherapy response, affective disorder, 51:297
- psychotherapy response, temperature, 51:297
- sleep, affective disorder, 51:297
- sleep, fluoxetine, 51:297
- social rhythm measurement, stress, 51:33
- stress, social rhythm measurement, 51:33
- temperature, affective disorder, 51:297
- temperature, childhood disorders, 52:273
- temperature, epilepsy, 52:273
- temperature, imipramine, 51:297
- temperature, melatonin, 52:273
- temperature, psychotherapy response, 51:297

**Circadian rhythms** continued

treatment outcome, antidepressants, 52:85  
 treatment outcome, motor activity, 52:85  
 wheel running, clorgyline, 53:173

**Circannual rhythms**

affective disorder, suicide, 53:161  
 affective disorder, sunshine hours, 53:161  
 affective disorder, weather, 53:161  
 eating disorder, sleep, 52:71  
 eating disorder, latitude, 52:71  
 eating disorder, mood, 52:71  
 eating disorder, seasonal affective disorder, 52:71  
 latitude, eating disorder, 52:71  
 latitude, mood, 52:71  
 latitude, seasonal affective disorder, 52:71  
 mood, eating disorder, 52:71  
 mood, latitude, 52:71  
 postexercise heat loss, seasonal affective disorder, 52:199  
 postexercise heat loss, temperature regulation, 52:199  
 seasonal affective disorder, eating disorder, 52:71  
 seasonal affective disorder, latitude, 52:71  
 seasonal affective disorder, postexercise heat loss, 52:199  
 seasonal affective disorder, temperature regulation, 52:199  
 sleep, eating disorder, 52:71  
 suicide, affective disorder, 53:161  
 suicide, sunshine hours, 53:161  
 suicide, weather, 53:161  
 sunshine hours, affective disorder, 53:161  
 sunshine hours, suicide, 53:161  
 temperature regulation, postexercise heat loss, 52:199  
 temperature regulation, seasonal affective disorder, 52:199  
 weather, affective disorder, 53:161  
 weather, suicide, 53:161  
 weather, sunshine hours, 53:161

**Clomipramine**

affective disorder, desmethylclomipramine metabolite, 54:161  
 affective disorder, rapid eye movement sleep rebound, 54:161  
 affective disorder, sleep, 54:161  
 obsessive-compulsive disorder, symptom severity, 51:203  
 obsessive-compulsive disorder, treatment response, 51:203

**Clomipramine** continued

rapid eye movement sleep rebound, affective disorder, 54:161  
 rapid eye movement sleep rebound, desmethylclomipramine metabolite, 54:161  
 sleep, affective disorder, 54:161  
 sleep, desmethylclomipramine metabolite, 54:161  
 symptom severity, obsessive-compulsive disorder, 51:203  
 treatment response, obsessive-compulsive disorder, 51:203

**Clonidine**

affective disorder, growth hormone, 52:115  
 affective disorder, suicide attempts, 52:115  
 growth hormone, affective disorder, 52:115  
 growth hormone response, paranoid schizophrenia subtype, 53:231  
 growth hormone response, schizophrenia, 53:231  
 growth hormone, suicide attempts, 52:115  
 paranoid subtype, schizophrenia, 53:231  
 prolactin, schizophrenia, 53:231  
 schizophrenia, growth hormone response, 53:231  
 suicide attempts, affective disorder, 52:115  
 suicide attempts, growth hormone, 52:115

**Clorgyline**

circadian period lengthened, wheel running, 53:173  
 monoamine oxidase inhibitors, hamsters, 53:173

**Collagen stimulation**

schizophrenia, arachidonic acid platelet aggregation response, 54:13  
 adenosine triphosphate release in blood, haloperidol, 54:13

**Computed tomography**

cortical atrophy, gender, 53:41  
 cortical atrophy, genetics, 53:41  
 cortical atrophy, schizophrenia, 53:41  
 cortical atrophy, ventricle-brain ratio, 53:41  
 gender, cortical atrophy, 53:41  
 gender, schizophrenia, 53:41  
 gender, ventricle-brain ratio, 53:41  
 genetics, cortical atrophy, 53:41  
 genetics, ventricle-brain ratio, 53:41  
 schizophrenia, cortical atrophy, 53:41  
 schizophrenia, gender, 53:41  
 schizophrenia, genetics, 53:41  
 schizophrenia, ventricle-brain ratio, 53:41  
 ventricle-brain ratio, gender, 53:41

**Computed tomography** continued

ventricle-brain ratio, genetics, 53:41  
 ventricle-brain ratio, schizophrenia, 53:41

**Conduct disorder**

pictorial instrument for psychopathology assessment, children, 51:87

**Control subjects**

heart rate, lactate infusion, 54:97  
 research methodology, recruitment criteria, 53:301

**Corticotropin releasing factor**

monoamines, cerebrospinal fluid, 52:103  
 substance abuse, cannabinol use, 52:103

**Cortisol**

adrenocorticotrophic hormone, affective disorder, 51:185  
 adrenocorticotrophic hormone, dexamethasone, 51:185  
 adrenocorticotrophic hormone, melancholic subtype, 51:185  
 affective disorder, adrenocorticotrophic hormone, 51:185  
 affective disorder, dexamethasone, 51:185  
 affective disorder, melancholic subtype, 51:185  
 dexamethasone, adrenocorticotrophic hormone, 51:185  
 dexamethasone, affective disorder, 51:185  
 dexamethasone, melancholic subtype, 51:185  
 dysphoria, post-partum, 54:241  
 epidural anesthesia, dysphoria, 54:241  
 epidural anesthesia, mood, 54:241  
 epidural anesthesia, postpartum blues, highs, 54:241  
 melancholic subtype, adrenocorticotrophic hormone, 51:185  
 melancholic subtype, affective disorder, 51:185  
 melancholic subtype, dexamethasone, 51:185  
 meta-chlorophenylpiperazine, panic symptoms, 53:219, 54:115  
 mood, epidural anesthesia, 54:241  
 mood, postpartum dysphoria, 54:241  
 panic symptoms, meta-chlorophenylpiperazine, 53:219, 54:115  
 postpartum dysphoria, epidural anesthesia, 54:241

**Cross-cultural comparisons**

adolescents in Japan and America, self-administered depression scale, 53:275  
 antidepressant outcome, Asian-Americans, 53:289

**Cross-cultural comparisons** continued

antidepressant outcome, client-therapist ethnic match, 53:289  
 Asian-Americans, antidepressant outcome, 53:289  
 Asian-Americans, client-therapist ethnic match, 53:289  
 client-therapist ethnic match, antidepressant outcome, 53:289  
 client-therapist ethnic match, Asian-Americans, 53:289  
 depressed mood, English-Japanese-Spanish depression scale, 53:259  
 depressed mood, gender differences, 53:259  
 English-Japanese-Spanish depression scale, depressed mood, 53:259  
 English-Japanese-Spanish depression scale, gender differences, 53:259  
 gender differences, depressed mood, 53:259  
 gender differences, English-Japanese-Spanish depression scale, 53:259  
 self-administered depression scale, adolescents in Japan and America, 53:275

**Cytokines**

schizophrenia, autoantibodies, 51:1

**Depression. See Affective disorder****Dermatoglyphics**

attention, continuous performance test, 53:119  
 attention, minor physical anomalies, 53:119  
 attention, schizophrenia, 53:119  
 attention, second trimester development, 53:119  
 continuous performance test, schizophrenia, 53:119  
 minor physical anomalies, attention, 53:119  
 schizophrenia, second trimester development, 53:119  
 second trimester development, minor physical anomalies, 53:119

**Desmethylclomipramine**

affective disorder, clomipramine, 54:161  
 clomipramine, rapid eye movement sleep rebound, 54:161  
 clomipramine metabolites, sleep, 54:161  
 rapid eye movement sleep rebound, affective disorder, 54:161  
 sleep, affective disorder, 54:161  
 sleep, clomipramine pulse-loading, 54:161

**Desmethylimipramine**

circadian period shortened, hamster, 53:173

**Desmethylimipramine** continued

affective disorder, lithium, 51:283  
 affective disorder, sleep deprivation, 51:283  
 affective disorder, treatment response, 51:283  
 lithium, affective disorder, 51:283  
 sleep deprivation, lithium, 51:283  
 sleep deprivation, treatment response, 51:283  
 treatment response, sleep deprivation, 51:283

**Dexamethasone suppression test**

adrenocorticotrophic hormone, affective disorder, 51:185  
 adrenocorticotrophic hormone, cortisol, 51:185  
 affective disorder, adrenocorticotrophic hormone, 51:185  
 affective disorder, cortisol, 51:185  
 affective disorder, melancholic subtype, 51:185  
 affective disorder, thyroid hormones, 51:185  
 cortisol, adrenocorticotrophic hormone, 51:185  
 gender, affective disorder, 51:185  
 thyroid hormones, affective disorder, 51:185

**Dichotic listening**

attention, electromyography, 51:127  
 attention, facial expression, 51:127  
 attention, mood, 51:127  
 electromyography, attention, 51:127  
 facial expression, electromyography, 51:127  
 mood, electromyography, 51:127

**Dihydroxyphenylacetic acid**

schizophrenia, symptom severity, 52:251

**Dopamine. See also Homovanillic acid,**

Dihydroxyphenylacetic acid  
 affective disorder, D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, 52:149  
 D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, linkage analysis, 51:215  
 D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, schizophrenia, 51:215  
 D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, affective disorder, 52:149  
 D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, linkage analysis, 52:149  
 D<sub>2</sub> receptor gene, linkage analysis, 53:203  
 D<sub>3</sub> receptor gene, schizophrenia, 53:203  
 D<sub>4</sub> receptor gene, genetics, 53:77  
 D<sub>4</sub> receptor gene, linkage analysis, 53:77  
 D<sub>4</sub> receptor gene, schizophrenia, 53:77  
 dopamine transporter gene (DAT1), tandem repeats in schizophrenia, 52:17

**Dopamine** continued

genetics, affective disorder, 52:149  
 genetics, D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 genetics, D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, 52:149  
 genetics, D<sub>4</sub> receptor gene, 53:77  
 genetics, linkage analysis, 51:215, 52:149, 53:77  
 genetics, schizophrenia, 51:215, 52:17, 53:77  
 genetics, tandem repeats, 52:17  
 linkage analysis, affective disorder, 52:149  
 linkage analysis, D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 linkage analysis, D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci, 52:149  
 linkage analysis, D<sub>2</sub> receptor gene, 53:203  
 linkage analysis, D<sub>4</sub> receptor gene, 53:77  
 linkage analysis, schizophrenia, 51:215, 53:203, 53:77  
 schizophrenia, D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 schizophrenia, D<sub>2</sub> receptor gene, 53:203  
 schizophrenia, D<sub>4</sub> receptor gene, 53:77  
 schizophrenia, genetics, 51:215, 52:17, 53:77  
 schizophrenia, linkage analysis, 51:215, 53:203, 53:77  
 schizophrenia, tandem repeats, 52:17  
 tandem repeats, genetics, 52:17  
 tandem repeats in schizophrenia, dopamine transporter gene (DAT1), 52:17

**Down's syndrome**  
 depressed mood, genetics, 52:25  
 serotonin in plasma, depressed mood, 52:25

**Eating disorders**  
 circannual rhythms, latitude, 52:71  
 circannual rhythms, mood, 52:71  
 circannual rhythms, seasonal affective disorder, 52:71  
 homovanillic acid, 3-methoxy-4-hydroxyphenylethleneglycol, 52:11  
 homovanillic acid, psychotic symptoms, 52:11  
 latitude, circannual rhythms, 52:71  
 latitude, mood, 52:71  
 latitude, seasonal affective disorder, 52:71  
 3-methoxy-4-hydroxyphenylethleneglycol, homovanillic acid, 52:11  
 3-methoxy-4-hydroxyphenylethleneglycol, psychotic symptoms, 52:11  
 mood, circannual rhythms, 52:71  
 mood, latitude, 52:71  
 psychotic symptoms, homovanillic acid, 52:11  
 psychotic symptoms, 3-methoxy-4-hydroxyphenylethleneglycol, 52:11

**Eating disorders** continued

seasonal affective disorder, circannual rhythms, 52:71  
 seasonal affective disorder, latitude, 52:71

**Electroencephalography**

acquired immune deficiency syndrome, fronto-occipital coherence, 54:1  
 acquired immune deficiency syndrome, neuropsychological performance, 54:1  
 alcoholism, cingulate gyrus, 54:225  
 alcoholism, Korsakoff's syndrome, 54:225  
 alcoholism, positron emission tomography, 54:225  
 cingulate gyrus, alcoholism, 54:225  
 cingulate gyrus, positron emission tomography, 54:225  
 fronto-occipital coherence, neuropsychological performance, 54:1  
 Korsakoff's syndrome, cingulate gyrus, 54:225  
 Korsakoff's syndrome, positron emission tomography, 54:225  
 neuropsychological performance, acquired immune deficiency syndrome, 54:1  
 positron emission tomography, alcoholism, 54:225  
 positron emission tomography, cingulate gyrus, 54:225

**Electroconvulsive therapy**

affective disorder, magnetic resonance imaging, 54:177  
 affective disorder, memory, 54:177  
 affective disorder, thalamus, 54:177  
 isoproterenol treatment, melatonin, 53:185  
 isoproterenol treatment, rat, 53:185  
 magnetic resonance imaging, affective disorder, 54:177  
 magnetic resonance imaging, memory, 54:177  
 magnetic resonance imaging, thalamus, 54:177  
 melatonin, isoproterenol treatment, 53:185  
 melatonin, rat, 53:185  
 memory, affective disorder, 54:177  
 memory, thalamus, 54:177  
 rat, isoproterenol treatment, 53:185  
 thalamus, magnetic resonance imaging, 54:177  
 thalamus, memory, 54:177

**Electromyography**

affective disorder, facial expression, 51:127  
 affective disorder, positive vs. neutral words, 51:127  
 attention, dichotic listening, 51:127  
 attention, facial expression, 51:127  
 dichotic listening, facial expression, 51:127  
 dichotic listening, mood, 51:127

**Electromyography** continued

facial expression, affective disorder, 51:127  
 facial expression, positive vs. neutral words, 51:127  
 mood, facial expression, 51:127

**Epilepsy**

childhood disorders, circadian rhythms, 52:273  
 childhood disorders, melatonin, 52:273  
 childhood disorders, temperature, 52:273  
 circadian rhythms, melatonin, 52:273  
 circadian rhythms, temperature, 52:273  
 magnetic resonance imaging, putamen, 54:295  
 magnetic resonance imaging, stereological sampling, 54:295  
 magnetic resonance imaging, temporal lobe, 54:295  
 melatonin, childhood disorders, 52:273  
 melatonin, circadian rhythms, 52:273  
 melatonin, temperature, 52:273  
 putamen, magnetic resonance imaging, 54:295  
 putamen, stereological sampling, 54:295  
 temperature, childhood disorders, 52:273  
 temperature, circadian rhythms, 52:273  
 temperature, melatonin, 52:273  
 temporal lobe, magnetic resonance imaging, 54:295  
 temporal lobe, stereological sampling, 54:295

**Epinephrine**

schizophrenia, cerebrospinal fluid, 52:237

**Eye movements**

alcohol abuse, smooth pursuit tracking, 52:99  
 anticipatory saccades, neuroleptic treatment, 54:185  
 anticipatory saccades, schizophrenia, 54:185  
 neuroleptic treatment, smooth pursuit tracking, 54:185  
 schizophrenia, neuroleptic treatment, 54:185  
 schizophrenia, smooth pursuit tracking, 54:185  
 smooth pursuit tracking, alcohol abuse, 52:99  
 smooth pursuit tracking, neuroleptic treatment, 54:185  
 smooth pursuit tracking, schizophrenia, 54:185

**Facial expression**

affective disorder, electromyography, 51:127  
 affective disorder, positive vs. neutral words, 51:127  
 attention, electromyography, 51:127  
 cerebral blood flow, facial mood discrimination test, 52:215  
 dichotic listening, attention, 51:127  
 dichotic listening, electromyography, 51:127  
 electromyography, dichotic listening, 51:127

**Facial expression** continued

- electromyography, mood, 51:127
- electromyography, positive vs. neutral words, 51:127
- facial discrimination test, cerebral blood flow, 52:215
- mood, attention, 51:127
- mood, electromyography, 51:127
- mood induction, laterality of cerebral blood flow, 52:215

**Factor analysis**

- schizophrenia, neuropsychological performance, 54:51
- schizophrenia, positive symptoms, 54:51
- schizophrenia, intelligence, 54:51
- neuropsychological performance, schizophrenia, 54:51
- neuropsychological performance, positive symptoms, 54:51
- neuropsychological performance, intelligence, 54:51
- positive symptoms, schizophrenia, 54:51
- positive symptoms, neuropsychological performance, 54:51
- positive symptoms, intelligence, 54:51
- intelligence, schizophrenia, 54:51
- intelligence, neuropsychological performance, 54:51
- intelligence, positive symptoms, 54:51

**Fibroblasts**

- schizophrenia, skin fibroblasts, 53:87

**Fluoxetine**

- affective disorder, circadian temperature rhythm, 51:297
- affective disorder, rapid eye movement sleep latency, 52:327
- affective disorder, sleep, 51:297, 52:327
- affective disorder, treatment response prediction, 52:327
- circadian rhythms, hamster wheel running, 53:173
- circadian temperature rhythm, affective disorder, 51:297
- circadian temperature rhythm, sleep, 51:297
- rapid eye movement sleep latency, affective disorder, 52:327
- rapid eye movement sleep latency, treatment response prediction, 52:327
- sleep, affective disorder, 51:297, 52:327
- sleep, circadian temperature rhythm, 51:297
- sleep, treatment response prediction, 52:327
- treatment response prediction, rapid eye movement sleep latency, 52:327

**Fluoxetine** continued

- treatment response prediction, sleep, 52:327

**Folate**

- affective disorder, antidepressant response, 53:313
- antidepressant response, symptom severity, 53:313

**Frontal lobe**

- cerebral blood flow, drug-naïve patients, 53:57
- cerebral blood flow, schizophrenia, 53:57
- executive functions, schizophrenia, 52:265
- family history, genetics, 54:37
- family history, neuropsychological performance, 54:37
- family history, schizophrenia, 54:37
- gender, glucose metabolic rate, 51:175
- gender, positron emission tomography, 51:175
- genetics, family history, 54:37
- genetics, neuropsychological performance, 54:37
- genetics, schizophrenia, 54:37
- neuropsychological performance, family history, 54:37

- neuropsychological performance, genetics, 54:37
- neuropsychological performance, schizophrenia, 54:37
- positron emission tomography, gender, 51:175
- positron emission tomography, glucose metabolic rate, 51:175

**rat, microdialysis, 52:285**

- rat, serotonin, 52:285
- schizophrenia, cerebral blood flow, 53:57
- schizophrenia, drug-naïve patients, 53:57
- schizophrenia, executive functions, 52:265
- schizophrenia, family history, 54:37
- schizophrenia, genetics, 54:37
- schizophrenia, neuropsychological performance, 54:37
- serotonin, microdialysis, 52:285
- serotonin, rat, 52:285

**Galanthamine hydrobromide**

- sleep, cholinergic system, 51:253
- cholinergic system, rapid eye movement sleep latency, 51:253
- rapid eye movement sleep latency, cholinesterase inhibitors, 51:253

**Gender**

- affective disorder, arecoline, 51:269
- affective disorder, dexamethasone, 51:185
- arecoline, affective disorder, 51:269

**Gender** continued

attention deficit disorder, depressed mood, 53:13  
 brain size, intelligence, 53:243  
 brain size, magnetic resonance imaging, 53:243  
 brain size, schizophrenia, 53:243  
 brain size, symptom severity, 53:243  
 computed tomography, cortical atrophy, 53:41  
 computed tomography, genetics, 53:41  
 computed tomography, schizophrenia, 53:41  
 cortical atrophy, genetics, 53:41  
 cortical atrophy, schizophrenia, 53:41  
 depressed mood, attention deficit disorder, 53:13  
 depressive symptoms, Japanese and American  
 adolescents, 53:259  
 dexamethasone, affective disorder, 51:185  
 frontal lobe, glucose metabolic rate, 51:175  
 frontal lobe, positron emission tomography,  
 51:175  
 genetics, computed tomography, 53:41  
 genetics, cortical atrophy, 53:41  
 genetics, lifetime risk of affective disorder, 52:125  
 genetics, schizophrenia, 52:125, 53:41  
 genetics, ventricle-brain ratio, 53:41  
 intelligence, brain size, 53:243  
 intelligence, magnetic resonance imaging, 53:243  
 intelligence, schizophrenia, 53:243  
 intelligence, symptom severity, 53:243  
 Japanese and American adolescents, depressive  
 symptoms, 53:259  
 Japanese and American adolescents, mood, 53:259  
 lifetime risk of affective disorder, schizophrenia,  
 52:125  
 magnetic resonance imaging, brain size, 53:243  
 magnetic resonance imaging, intelligence, 53:243  
 magnetic resonance imaging, schizophrenia, 53:243  
 magnetic resonance imaging, symptom severity,  
 53:243  
 meta-chlorophenylpiperazine, prolactin, 54:115  
 mood, Japanese and American adolescents, 53:259  
 positron emission tomography, frontal lobe, 51:175  
 positron emission tomography, glucose metabolic  
 rate, 51:175  
 prolactin, meta-chlorophenylpiperazine, 54:115  
 schizophrenia, brain size, 53:243  
 schizophrenia, computed tomography, 53:41  
 schizophrenia, cortical atrophy, 53:41  
 schizophrenia, genetics, 52:125, 53:41  
 schizophrenia, intelligence, 53:243  
 schizophrenia, magnetic resonance imaging, 53:243  
 schizophrenia, symptom severity, 53:243  
 schizophrenia, ventricle-brain ratio, 53:41  
 symptom severity, brain size, 53:243

**Gender** continued

symptom severity, intelligence, 53:243  
 ventricle-brain ratio, genetics, 53:41  
 ventricle-brain ratio, schizophrenia, 53:41

**Genetics**

adenosine triphosphate, affective disorder,  
 53:111  
 adenosine triphosphate, family members,  
 53:111  
 adenosine triphosphate, lymphoblastoid cells,  
 53:111  
 affective disorder, adenosine triphosphate,  
 53:111  
 affective disorder, bipolar disorder, 53:111  
 affective disorder, dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub>  
 receptor gene loci, 52:149  
 affective disorder, family members, 53:111  
 affective disorder, linkage analysis, 52:149  
 affective disorder, lymphoblastoid cells, 53:111  
 attention, continuous performance test, 54:259  
 attention, siblings of schizophrenics, 54:259  
 autism, family history, serotonin in plasma, 52:25  
 bipolar disorder, adenosine triphosphate, 53:111  
 bipolar disorder, family members, 53:111  
 bipolar disorder, lymphoblastoid cells, 53:111  
 computed tomography, cortical atrophy, 53:41  
 computed tomography, gender, 53:41  
 computed tomography, schizophrenia, 53:41  
 computed tomography, ventricle-brain ratio, 53:41  
 continuous performance test, attention, 54:259  
 continuous performance test, siblings of  
 schizophrenics, 54:259  
 cortical atrophy, gender, 53:41  
 cortical atrophy, schizophrenia, 53:41  
 depressed mood, Down's syndrome, 52:25  
 depressed mood, serotonin in plasma, 52:25  
 dopamine, affective disorder, 52:149  
 dopamine, D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 dopamine, D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor gene loci,  
 52:149  
 dopamine, D<sub>4</sub> receptor gene, 53:77  
 dopamine, linkage analysis, 51:215, 52:149, 53:77  
 dopamine, schizophrenia, 51:215, 53:77  
 dopamine transporter gene, schizophrenia, 52:17  
 dopamine transporter gene, tandem repeats, 52:17  
 Down's syndrome, depressed mood, 52:25  
 Down's syndrome, serotonin in plasma, 52:25  
 family history, frontal lobe tasks, 54:37  
 family history, neuropsychological performance,  
 54:37  
 family history, schizophrenia, 54:37

**Genetics** continued

family members, adenosine triphosphate, 53:111  
 family members, affective disorder, 53:111  
 family members, bipolar disorder, 53:111  
 family members, lymphoblastoid cells, 53:111  
 frontal lobe tasks, family history, 54:37  
 frontal lobe tasks, neuropsychological performance, 54:37  
 frontal lobe tasks, schizophrenia, 54:37  
 gender, computed tomography, 53:41  
 gender, cortical atrophy, 53:41  
 gender, lifetime risk of affective disorder, 52:125  
 gender, schizophrenia, 52:125, 53:41  
 gender, ventricle-brain ratio, 53:41  
 laterality, familial and sporadic cases, 54:25  
 laterality, magnetic resonance imaging, 54:25  
 laterality, schizophrenia, 54:25  
 laterality, ventricle size, 54:25  
 lifetime risk of affective disorder, gender, 52:125  
 lifetime risk of affective disorder, schizophrenia, 52:125  
 linkage analysis, affective disorder, 52:149  
 linkage analysis, dopamine, 51:215, 52:149, 53:77  
 linkage analysis, pseudoautosomal locus DXYS14, 52:135  
 linkage analysis, schizophrenia, 51:215, 52:135, 53:77  
 lymphoblastoid cells, adenosine triphosphate, 53:111  
 lymphoblastoid cells, affective disorder, 53:111  
 lymphoblastoid cells, bipolar disorder, 53:111  
 lymphoblastoid cells, family members, 53:111  
 magnetic resonance imaging, familial and sporadic cases, 54:25  
 magnetic resonance imaging, laterality, 54:25  
 magnetic resonance imaging, schizophrenia, 54:25  
 magnetic resonance imaging, ventricular size, 54:25  
 neuropsychological performance, family history, 54:37  
 neuropsychological performance, frontal lobe tasks, 54:37  
 neuropsychological performance, nonpsychotic relatives, 53:1  
 neuropsychological performance, schizophrenia, 53:1, 54:37  
 neuropsychological performance, schizotypal personality disorder, 53:1  
 pseudoautosomal locus DXYS14, linkage analysis, 52:135  
 pseudoautosomal locus DXYS14, schizophrenia, 52:135  
 schizophrenia, computed tomography, 53:41  
 schizophrenia, cortical atrophy, 53:41

**Genetics** continued

schizophrenia, dopamine D<sub>1</sub>-D<sub>2</sub>-D<sub>4</sub> receptor genes, 51:215  
 schizophrenia, dopamine D<sub>4</sub> receptor gene, 53:77  
 schizophrenia, dopamine transporter gene (DAT1), 52:17  
 schizophrenia, familial and sporadic cases, 54:25  
 schizophrenia, family history, 54:37  
 schizophrenia, frontal lobe tasks, 54:37  
 schizophrenia, gender, 52:125, 53:41  
 schizophrenia, laterality, 54:25  
 schizophrenia, lifetime risk of affective disorder, 52:125  
 schizophrenia, linkage analysis, 51:215, 52:135, 53:77  
 schizophrenia, magnetic resonance imaging, 54:25  
 schizophrenia, neuropsychological performance, 54:37, 53:1  
 schizophrenia, nonpsychotic relatives, 53:1  
 schizophrenia, pseudoautosomal locus DXYS14, 52:135  
 schizophrenia, schizotypal personality disorder, 53:1  
 schizophrenia, ventricular size, 54:25, 53:41  
 schizotypal personality disorder, neurological tests, 53:1  
 schizotypal personality disorder, nonpsychotic relatives, 53:1  
 schizotypal personality disorder, schizophrenia, 53:1  
 serotonin in plasma, autism, family history, 52:25  
 serotonin in plasma, depressed mood, 52:25  
 serotonin in plasma, Down's syndrome, 52:25  
 siblings of schizophrenics, attention, 54:259  
 siblings of schizophrenics, continuous performance test, 54:259  
 tandem repeats, dopamine transporter gene (DAT1), schizophrenia, 52:17  
 ventricular size, familial and sporadic cases, 54:25  
 ventricular size, laterality, 54:25  
 ventricular size, magnetic resonance imaging, 54:25  
 ventricular size, schizophrenia, 54:25  
 ventricle-brain ratio, computed tomography, 53:41  
 ventricle-brain ratio, gender, 53:41  
 ventricle-brain ratio, schizophrenia, 53:41

**Glucose metabolic rate**

frontal lobe, gender, 51:175  
 gender, positron emission tomography, 51:175  
 positron emission tomography, frontal lobe, 51:175

**Growth hormone**

affective disorder, arecoline, 51:269  
 affective disorder, clonidine response, 52:115

**Growth hormone** continued

- affective disorder, suicide attempts, 52:115
- alprazolam, anxiety symptoms, 53:219
- alprazolam, meta-chlorophenylpiperazine, 53:219
- anxiety symptoms, alprazolam, 53:219
- anxiety symptoms, meta-chlorophenylpiperazine, 53:219
- apomorphine, positive symptoms, 53:231
- apomorphine, prolactin, 53:231
- apomorphine, schizophrenia, 53:231
- arecoline, affective disorder, 51:269
- clonidine, paranoid subtype, 53:231
- clonidine response, affective disorder, 52:115
- clonidine response, suicide attempts, 52:115
- clonidine, schizophrenia, 53:231
- meta-chlorophenylpiperazine, alprazolam, 53:219
- meta-chlorophenylpiperazine, anxiety symptoms, 53:219
- meta-chlorophenylpiperazine, panic disorder, 54:115
- meta-chlorophenylpiperazine, serotonin, 54:115
- panic disorder, meta-chlorophenylpiperazine, 54:115
- panic disorder, serotonin, 54:115
- paranoid subtype, clonidine, 53:231
- paranoid subtype, schizophrenia, 53:231
- positive symptoms, schizophrenia, 53:231
- prolactin, apomorphine, 53:231
- prolactin, positive symptoms, 53:231
- prolactin, schizophrenia, 53:231
- schizophrenia, apomorphine, 53:231
- schizophrenia, clonidine, 53:231
- schizophrenia, paranoid subtype, 53:231
- schizophrenia, positive symptoms, 53:231
- schizophrenia, prolactin, 53:231
- serotonin, meta-chlorophenylpiperazine, 54:115
- serotonin, panic disorder, 54:115
- suicide attempts, affective disorder, 52:115
- suicide attempts, clonidine response, 52:115

**Haloperidol**

- defecation bolus counts, rat, 54:87
- motor activity, rat, 54:87
- platelet aggregation, schizophrenia, 54:13
- rat, defecation bolus counts, 54:87
- rat, motor activity, 54:87
- schizophrenia, platelet aggregation, 54:13
- schizophrenia, treatment response, 52:107

**Hamilton Rating Scale for Anxiety**

- interrater reliability, structured interview guide, 53:191

**Hamster**

- antidepressant treatment, circadian rhythms, 53:173

**Hamster** continued

- circadian rhythms, antidepressant treatment, 53:173

**Heart rate**

- arecoline, blood pressure, 51:269
- arecoline, cholinergic system, 51:269
- arecoline, rapid eye movement sleep latency, 51:269
- blood pressure, arecoline, 51:269
- blood pressure, rapid eye movement sleep latency, 51:269
- cerebral blood flow, mood induction, 52:215
- cholinergic system, arecoline, 51:269
- cholinergic system, blood pressure, 51:269
- cholinergic system, rapid eye movement sleep latency, 51:269
- lactate infusion, normal subjects, 54:97
- marijuana, motor performance, 51:115
- mood induction, cerebral blood flow, 52:215
- rapid eye movement sleep latency, arecoline, 51:269
- rapid eye movement sleep latency, blood pressure, 51:269
- rapid eye movement sleep latency, cholinergic system, 51:269
- spectral analysis, sympathovagal ratios, 54:97

**Hippocampus**

- alpha-amino-3-methyl-isoxazole-4-propionate receptor, antidepressant treatment, 51:107
- alpha-amino-3-methyl-isoxazole-4-propionate receptor, phospholipase A2, 51:107
- alpha-amino-3-methyl-isoxazole-4-propionate receptor, rat, 51:107
- alpha-amino-3-methyl-isoxazole-4-propionate receptor, trimipramine, 51:107
- antidepressant treatment, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107
- antidepressant treatment, phospholipase A2, 51:107
- antidepressant treatment, rat, 51:107
- antidepressant treatment, trimipramine, 51:107
- magnetic resonance imaging, schizophrenia, 54:25
- phospholipase A2, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107
- phospholipase A2, antidepressant treatment, 51:107
- phospholipase A2, rat, 51:107
- phospholipase A2, trimipramine, 51:107
- schizophrenia, magnetic resonance imaging, 54:25
- trimipramine, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107
- trimipramine, phospholipase A2, 51:107
- trimipramine, rat, 51:107

**Homovanillic acid**

affective disorder, moclobemide treatment response, 52:259  
 aggression, attention deficit disorder, 52:305  
 attention deficit disorder, aggression, 52:305  
 cannabinol use, substance abuse, 52:103  
 cerebrospinal fluid, schizophrenia, 52:237  
 eating disorders, 3-methoxy-4-hydroxyphenylethleneglycol, 52:11  
 eating disorders, psychotic symptoms, 52:11  
 3-methoxy-4-hydroxyphenylethleneglycol, eating disorders, 52:11  
 3-methoxy-4-hydroxyphenylethleneglycol, psychotic symptoms, 52:11  
 moclobemide treatment response, affective disorder, 52:259  
 psychotic symptoms, eating disorders, 52:11  
 psychotic symptoms, 3-methoxy-4-hydroxyphenylethleneglycol, 52:11  
 schizophrenia, cerebrospinal fluid, 52:237  
 substance abuse, cannabinol use, 52:103

**5-Hydroxyindoleacetic acid**

attention deficit disorder, impulsivity/hyperactivity, 52:305  
 affective disorder, moclobemide treatment response, 52:259  
 cannabinol use, substance abuse, 52:103  
 impulsivity/hyperactivity, attention deficit disorder, 52:305  
 moclobemide treatment response, affective disorder, 52:259  
 schizophrenia, cerebrospinal fluid, 52:237  
 substance abuse, cannabinol use, 52:103

**Hypothalamic-pituitary-adrenal axis**

adrenocorticotrophic hormone, affective disorder, 51:185  
 adrenocorticotrophic hormone, dexamethasone, 51:185  
 adrenocorticotrophic hormone, melancholic subtype, 51:185  
 affective disorder, adrenocorticotrophic hormone, 51:185  
 affective disorder, arecoline, 51:269  
 affective disorder, childhood, 51:269  
 affective disorder, dexamethasone, 51:185  
 affective disorder, melancholic subtype, 51:185  
 anxiety symptoms, meta-chlorophenylpiperazine, 54:115  
 anxiety symptoms, panic disorder, 54:115  
 arecoline, affective disorder, 51:269  
 arecoline, childhood depression, 51:269

**Hypothalamic-pituitary-adrenal axis** continued

cannabinol use, substance abuse, 52:103  
 childhood depression, arecoline, 51:269  
 cortisol, affective disorder, 51:185  
 cortisol, dexamethasone, 51:185  
 dexamethasone, adrenocorticotrophic hormone, 51:185  
 epidural anesthesia, mood, 54:241  
 epidural anesthesia, postpartum dysphoria, 54:241  
 meta-chlorophenylpiperazine, anxiety symptoms, 54:115  
 meta-chlorophenylpiperazine, panic disorder, 54:115  
 panic symptoms, meta-chlorophenylpiperazine, 53:219, 54:115  
 panic disorder, anxiety symptoms, 54:115  
 panic disorder, meta-chlorophenylpiperazine, 54:115  
 postpartum dysphoria, epidural anesthesia, 54:241  
 substance abuse, cannabinol use, 52:103

**Imipramine**

affective disorder, circadian rhythms, 51:297  
 circadian rhythms, psychotherapy response, 51:297  
 temperature, affective disorder, 51:297

**Immune function**

affective disorder, amino acids, 54:143  
 affective disorder, bereavement, 52:1  
 affective disorder, lymphocyte counts, 52:1  
 affective disorder, natural killer cells, 52:1  
 affective disorder, T-cells, 52:1  
 alcoholism, treatment effects, 54:307  
 amino acids, affective disorder, 54:143  
 bereavement, affective disorder, 52:1  
 bereavement, lymphocyte counts, 52:1  
 bereavement, natural killer cells, 52:1  
 bereavement, T-cells, 52:1  
 interferon, affective disorder, 54:143  
 interferon, alcoholism, 54:307  
 interleukin, panic disorder, 54:135  
 interleukin, schizophrenia, 51:1  
 lymphocyte counts, affective disorder, 52:1  
 lymphocyte counts, bereavement, 52:1  
 lymphocyte counts, natural killer cells, 52:1  
 lymphocyte counts, T-cells, 52:1  
 natural killer cells, affective disorder, 52:1  
 natural killer cells, bereavement, 52:1  
 natural killer cells, lymphocyte counts, 52:1  
 natural killer cells, T-cells, 52:1  
 panic disorder, alprazolam, 54:135  
 panic disorder, symptom severity, 54:135  
 schizophrenia, age, 51:1  
 schizophrenia, duration of illness, 51:1  
 schizophrenia, neuroleptics, 51:1

**Immune function** continued

- T-cells, affective disorder, 52:1
- T-cells, bereavement, 52:1
- T-cells, lymphocyte counts, 52:1
- T-cells, natural killer cells, 52:1
- treatment effects, alcoholism, 54:307
- tryptophan, affective disorder, 54:143
- tryptophan, neopterin, 54:143

**Inositol**

- lithium treatment, cerebrospinal fluid, 53:103

**Intelligence**

- affective disorder, delayed vs. immediate recall, 51:231
- affective disorder, memory, 51:231
- affective disorder, neuropsychology, 51:231
- attention deficit disorder, neuropsychological tests, 53:13
- brain size, gender, 53:243
- brain size, magnetic resonance imaging, 53:243
- brain size, schizophrenia, 53:243
- brain size, symptom severity, 53:243
- gender, brain size, 53:243
- gender, magnetic resonance imaging, 53:243
- gender, schizophrenia, 53:243
- gender, symptom severity, 53:243
- magnetic resonance imaging, brain size, 53:243
- magnetic resonance imaging, gender, 53:243
- magnetic resonance imaging, schizophrenia, 53:243
- magnetic resonance imaging, symptom severity, 53:243
- memory, affective disorder, 51:231
- memory, delayed vs. immediate recall, 51:231
- neuropsychological performance, affective disorder, 51:231
- neuropsychological performance, attention deficit disorder, 53:13
- neuropsychological performance, factor analysis, 54:51
- neuropsychological performance, memory, delayed vs. immediate recall, 51:231
- neuropsychological performance, positive symptoms, 54:51
- neuropsychological performance, schizophrenia, 54:51
- nonpsychotic relatives, schizophrenia, 53:1
- positive symptoms, factor analysis, 54:51
- positive symptoms, neuropsychological performance, 54:51
- positive symptoms, schizophrenia, 54:51
- schizophrenia, brain size, 53:243
- schizophrenia, factor analysis, 54:51

**Intelligence** continued

- schizophrenia, gender, 53:243
- schizophrenia, magnetic resonance imaging, 53:243
- schizophrenia, neuropsychological performance, 54:51
- schizophrenia, nonpsychotic relatives, 53:1
- schizophrenia, positive symptoms, 54:51
- schizophrenia, symptom severity, 53:243

**Interferon**

- affective disorder, neopterin, 54:143
- affective disorder, tryptophan, 54:143
- alcoholism, treatment effects, 54:307
- neopterin, affective disorder, 54:143
- neopterin, tryptophan, 54:143
- treatment effects, alcoholism, 54:307
- tryptophan, affective disorder, 54:143
- tryptophan, neopterin, 54:143

**Interleukin**

- alprazolam, panic disorder, 54:135
- alprazolam, symptom severity, 54:135
- panic disorder, alprazolam, 54:135
- panic disorder, symptom severity, 54:135
- schizophrenia, age, 51:1
- schizophrenia, duration of illness, 51:1
- schizophrenia, neuroleptics, 51:1

**Isoproterenol**

- electroconvulsive shock, melatonin, 53:185
- melatonin, rat, 53:185
- rat, electroconvulsive shock, 53:185

**Kynurenone**

- cerebrospinal fluid, schizophrenia, 52:237
- neuroleptics, metanephrine, 52:251
- neuroleptics, schizophrenia, 52:251
- neuroleptics, treatment response, 52:251
- schizophrenia, cerebrospinal fluid, 52:237
- schizophrenia, metanephrine, 52:251
- schizophrenia, neuroleptics, 52:251
- schizophrenia, treatment response, 52:251

**Lactate infusion**

- blood pressure, normal subjects, 54:97
- heart rate, normal subjects, 54:97

**Laterality**

- cerebral blood flow, mood induction task, 52:215
- genetics, familial and sporadic cases, 54:25
- genetics, magnetic resonance imaging, 54:25
- genetics, schizophrenia, 54:25
- genetics, ventricular size, 54:25

**Laterality** continued

- magnetic resonance imaging, genetics, 54:25
- magnetic resonance imaging, schizophrenia, 54:25
- magnetic resonance imaging, ventricular size, 54:25
- mood induction task, cerebral blood flow, 52:215
- schizophrenia, familial and sporadic cases, 54:25
- schizophrenia, genetics, 54:25
- schizophrenia, magnetic resonance imaging, 54:25
- schizophrenia, ventricular size, 54:25
- ventricular size, genetics, 54:25
- ventricular size, magnetic resonance imaging, 54:25
- ventricular size, schizophrenia, 54:25

**Life events**

- age, bereavement, 51:33
- bereavement, circadian rhythm, 51:33
- circadian rhythm, depressive symptoms, 51:33
- depressive symptoms, mood, 51:33
- mood, age, 51:33

**Lithium**

- affective disorder, antidepressant treatment, 51:139
- affective disorder, desmethylimipramine, 51:283
- affective disorder, magnesium, 51:139
- affective disorder, 3-methoxy-4-hydroxyphenylethleneglycol, 51:51
- affective disorder, sleep deprivation, 51:283
- affective disorder, treatment response, 51:283
- antidepressant treatment, affective disorder, 51:139
- antidepressant treatment, magnesium, 51:139
- cerebrospinal fluid, inositol monophosphate, 53:103
- desmethylimipramine, affective disorder, 51:283
- desmethylimipramine, sleep deprivation, 51:283
- desmethylimipramine, treatment response, 51:283
- inositol monophosphate, cerebrospinal fluid, 53:103
- magnesium, affective disorder, 51:139
- magnesium, antidepressant treatment, 51:139
- 3-methoxy-4-hydroxyphenylethleneglycol, affective disorder, 51:51
- sleep deprivation, affective disorder, 51:283
- sleep deprivation, desmethylimipramine, 51:283
- sleep deprivation, treatment response, 51:283

**Lithium** continued

- treatment response, affective disorder, 51:283
- treatment response, desmethylimipramine, 51:283
- treatment response, sleep deprivation, 51:283

**Luteinizing hormone**

- posttraumatic stress disorder, East German refugees, 51:75

**Lymphocytes**

- affective disorder, bereavement, 52:1
- bereavement, immune function, 52:1
- immune function, natural killer cells, 52:1
- natural killer cells, T-cells, 52:1
- T-cells, affective disorder, 52:1

**Magnesium**

- affective disorder, antidepressant treatment, 51:139
- affective disorder, bipolar subtype, 51:139
- affective disorder, carbamazepine, 51:139
- affective disorder, lithium, 51:139
- amphetamine, attention deficit disorder, 54:199
- amphetamine, calcium in plasma, 54:199
- amphetamine, symptom response, 54:199
- antidepressant treatment, affective disorder, 51:139
- attention deficit disorder, amphetamine, 54:199
- attention deficit disorder, calcium in plasma, 54:199
- attention deficit disorder, methylphenidate, 54:199
- attention deficit disorder, symptom response, 54:199
- bipolar depression, carbamazepine, 51:139
- calcium in plasma, amphetamine, 54:199
- calcium in plasma, attention deficit disorder, 54:199
- carbamazepine, affective disorder, 51:139
- carbamazepine, bipolar depression, 51:139
- lithium, affective disorder, 51:139
- methylphenidate, attention deficit disorder, 54:199

**Magnetic resonance imaging**

- affective disorder, electroconvulsive therapy, 54:177
- affective disorder, memory, 54:177
- affective disorder, thalamus, 54:177
- age, geriatric patients, 54:283
- age, periventricular signal hyperintensity, 54:283
- age, putamen size, 52:35
- age, social phobia, 52:35
- age, visual hallucinations, 54:283
- amygdala size reduced, schizophrenia, 52:43
- brain size, gender, 53:243

**Magnetic resonance imaging** continued

- brain size, intelligence, 53:243
- brain size, schizophrenia, 53:243
- brain size, symptom severity, 53:243
- electroconvulsive therapy, affective disorder, 54:177
- electroconvulsive therapy, memory, 54:177
- electroconvulsive therapy, thalamus, 54:177
- epilepsy, putamen, 54:295
- epilepsy, stereological sampline, 54:294
- epilepsy, temporal lobe, 54:295
- gender, brain size, 53:243
- gender, intelligence, 53:243
- gender, schizophrenia, 53:243
- gender, symptom severity, 53:243
- genetics, laterality, 54:25
- genetics, schizophrenia, 54:25
- genetics, ventricular size, 54:25
- geriatric patients, age, 54:283
- geriatric patients, periventricular signal hyperintensity, 54:283
- geriatric patients, visual hallucinations, 54:283
- intelligence, brain size, 53:243
- intelligence, gender, 53:243
- intelligence, schizophrenia, 53:243
- laterality, genetics, 54:25
- laterality, schizophrenia, 54:25
- laterality, ventricular size, 54:25
- memory, affective disorder, 54:177
- memory, electroconvulsive therapy, 54:177
- memory, thalamus, 54:177
- periventricular signal hyperintensity, age, 54:283
- periventricular signal hyperintensity, geriatric patients, 54:283
- periventricular signal hyperintensity, visual hallucinations, 54:283
- putamen, epilepsy, 54:295
- putamen, schizophrenia, 52:43
- putamen size, age, 52:35
- putamen size, schizophrenia, 54:25
- putamen size, social phobia, 52:35
- putamen, stereological sampline, 54:294
- putamen, temporal lobe, 54:295
- schizophrenia, amygdala size reduced, 52:43
- schizophrenia, brain size, 53:243
- schizophrenia, familial and sporadic cases, 54:25
- schizophrenia, gender, 53:243
- schizophrenia, genetics, 54:25
- schizophrenia, intelligence, 53:243
- schizophrenia, laterality, 54:25
- schizophrenia, putamen, 52:43, 54:25
- schizophrenia, symptom severity, 53:243
- schizophrenia, temporal lobe, 52:43

**Magnetic resonance imaging** continued

- schizophrenia, ventricular size, 54:25
- social phobia, age, 52:35
- social phobia, putamen size, 52:35
- stereological sampline, epilepsy, 54:294
- stereological sampline, putamen, 54:295
- stereological sampline, temporal lobe, 54:295
- symptom severity, brain size, 53:243
- symptom severity, gender, 53:243
- symptom severity, intelligence, 53:243
- symptom severity, schizophrenia, 53:243
- temporal lobe, epilepsy, 54:295
- temporal lobe, putamen, 54:295
- temporal lobe, schizophrenia, 52:43
- temporal lobe, stereological sampline, 54:295
- thalamus, affective disorder, 54:177
- thalamus, electroconvulsive therapy, 54:177
- thalamus, memory, 54:177
- ventricular size, familial and sporadic cases, 54:25
- ventricular size, genetics, 54:25
- ventricular size, laterality, 54:25
- ventricular size, schizophrenia, 54:25
- visual hallucinations, age, 54:283
- visual hallucinations, geriatric patients, 54:283
- visual hallucinations, periventricular signal hyperintensity, 54:283

**Marijuana**

- heart rate, motor performance, 51:115
- memory, dose-response effect, 51:115
- neuropsychology, reaction time, 51:115

**Melatonin**

- childhood disorders, circadian rhythms, 52:273
- childhood disorders, epilepsy, 52:273
- childhood disorders, temperature, 52:273
- circadian rhythms, childhood disorders, 52:273
- circadian rhythms, epilepsy, 52:273
- circadian rhythms, temperature, 52:273
- electroconvulsive shock, isoproterenol treatment, 53:185
- electroconvulsive shock, rat, 53:185
- epilepsy, childhood disorders, 52:273
- epilepsy, circadian rhythms, 52:273
- epilepsy, temperature, 52:273
- isoproterenol treatment, electroconvulsive shock, 53:185
- isoproterenol treatment, rat, 53:185
- rat, isoproterenol treatment, 53:185
- temperature, childhood disorders, 52:273
- temperature, circadian rhythms, 52:273
- temperature, epilepsy, 52:273

**Memory**

affective disorder, delayed vs. immediate recall, 51:231  
 affective disorder, electroconvulsive therapy, 54:177  
 affective disorder, intelligence, 51:231  
 affective disorder, magnetic resonance imaging, 54:177  
 affective disorder, neuropsychology, 51:231  
 affective disorder, thalamus, 54:177  
 attention, schizophrenia, 53:141  
 attention, social cue perception, 53:141  
 attention, social skills training, 53:141  
 delayed vs. immediate recall, affective disorder, 51:231  
 delayed vs. immediate recall, intelligence, 51:231  
 electroconvulsive therapy, affective disorder, 54:177  
 electroconvulsive therapy, magnetic resonance imaging, 54:177  
 electroconvulsive therapy, thalamus, 54:177  
 intelligence, affective disorder, 51:231  
 intelligence, delayed vs. immediate recall, 51:231  
 magnetic resonance imaging, affective disorder, 54:177  
 magnetic resonance imaging, electroconvulsive therapy, 54:177  
 magnetic resonance imaging, thalamus, 54:177  
 marijuana, dose-response effect, 51:115  
 neuropsychology, affective disorder, 51:231  
 neuropsychology, delayed vs. immediate recall, 51:231  
 schizophrenia, attention, 53:141  
 schizophrenia, social cue perception, 53:141  
 schizophrenia, social skills training, 53:141  
 social cue perception, attention, 53:141  
 social cue perception, schizophrenia, 53:141  
 social cue perception, social skills training, 53:141  
 social skills training, attention, 53:141  
 social skills training, schizophrenia, 53:141  
 social skills training, social cue perception, 53:141  
 thalamus, affective disorder, 54:177  
 thalamus, electroconvulsive therapy, 54:177  
 thalamus, magnetic resonance imaging, 54:177

**Meta-chlorophenylpiperazine**

alprazolam, anxiety symptoms, 53:219  
 alprazolam, growth hormone, 53:219  
 anxiety symptoms, alprazolam, 53:219  
 anxiety symptoms, growth hormone, 53:219  
 anxiety symptoms, hypothalamic-pituitary-adrenal axis, 54:115

**Meta-chlorophenylpiperazine** continued

anxiety symptoms, panic disorder, 54:115  
 cortisol, panic symptoms, 53:219, 54:115  
 gender, prolactin, 54:115  
 growth hormone, alprazolam, 53:219  
 growth hormone, anxiety symptoms, 53:219  
 growth hormone, panic disorder, 54:115  
 growth hormone, serotonin, 54:115  
 healthy men, prolactin, 53:219  
 hypothalamic-pituitary-adrenal axis, anxiety symptoms, 54:115  
 hypothalamic-pituitary-adrenal axis, panic disorder, 54:115  
 panic symptoms, cortisol, 53:219  
 panic disorder, anxiety symptoms, 54:115  
 panic disorder, cortisol, 54:115  
 panic disorder, growth hormone, 54:115  
 panic disorder, hypothalamic-pituitary-adrenal axis, 54:115  
 panic disorder, serotonin, 54:115  
 phototherapy, seasonal affective disorder, 52:181  
 phototherapy, serotonin, 52:181  
 prolactin, gender, 54:115  
 prolactin, healthy men, 53:219  
 seasonal affective disorder, phototherapy, 52:181  
 seasonal affective disorder, serotonin, 52:181  
 serotonin, growth hormone, 54:115  
 serotonin, panic disorder, 54:115  
 serotonin, phototherapy, 52:181  
 serotonin, seasonal affective disorder, 52:181

**Metanephrine**

kyurenine pathway, neuroleptics, 52:251  
 kyurenine pathway, schizophrenia, 52:251  
 neuroleptics, kyurenine pathway, 52:251  
 neuroleptics, schizophrenia, 52:251  
 neuroleptics, treatment response, 52:251  
 schizophrenia, kyurenine pathway, 52:251  
 schizophrenia, neuroleptics, 52:251  
 schizophrenia, treatment response, 52:251

**Methionine**

affective disorder, serine, 51:11  
 affective disorder, taurine, 51:11  
 schizophrenia, serine challenge, 51:11  
 serine, affective disorder, 51:11  
 serine challenge, schizophrenia, 51:11  
 serine, plasmalevels, 51:11  
 taurine plasma levels, affective disorder, 51:11

**3-Methoxy-4-hydroxyphenylethleneglycol**

affective disorder, antidepressants, 51:51

**3-Methoxy-4-hydroxyphenylethleneglycol**

continued

- affective disorder, lithium treatment, 51:51
- affective disorder, moclobemide treatment response, 52:259
- affective disorder, sleep, 51:157
- affective disorder, unipolar subtype, 51:157
- antidepressants, affective disorder, 51:51
- attention deficit disorder, aggression, 52:305
- cannabinol use, substance abuse, 52:103
- eating disorders, homovanillic acid, 52:11
- eating disorders, psychotic symptoms, 52:11
- homovanillic acid, eating disorders, 52:11
- homovanillic acid, psychotic symptoms, 52:11
- lithium treatment, affective disorder, 51:51
- moclobemide treatment response, affective disorder, 52:259

neuroleptic treatment, schizophrenia, 51:51

psychotic symptoms, eating disorders, 52:11

psychotic symptoms, homovanillic acid, 52:11

schizoaffective disorder, plasma and cerebrospinal fluid, 51:51

schizophrenia, cerebrospinal fluid, 52:237

schizophrenia, neuroleptic treatment, 51:51

sleep, affective disorder, 51:157

substance abuse, cannabinol use, 52:103

unipolar depression, sleep 51:157

**Methylphenidate**

attention deficit disorder, magnesium, 54:199

magnesium, attention deficit disorder, 54:199

magnesium, red blood cells, 54:199

**Microdialysis**

frontal lobe, rat, 52:285

rat, serotonin, 52:285

serotonin, frontal lobe, 52:285

**Migration**

thyroxine, posttraumatic stress disorder, 51:61

**Moclobemide**

affective disorder, biogenic amines in plasma, 52:259

biogenic amines in plasma, monoamine oxidase inhibitors, 52:259

monoamine oxidase inhibitors, treatment response, 52:259

treatment response, affective disorder, 52:259

**Monoamine oxidase**

affective disorder, biogenic amines in plasma, 52:259

**Monoamine oxidase** continued

affective disorder, moclobemide, 52:259

affective disorder, treatment response, 52:259

biogenic amines in plasma, affective disorder, 52:259

biogenic amines in plasma, moclobemide, 52:259

biogenic amines in plasma, treatment response, 52:259

circadian rhythm, clorgyline, 53:173

clorgyline, circadian rhythm, 53:173

moclobemide, affective disorder, 52:259

moclobemide, biogenic amines in plasma, 52:259

moclobemide, treatment response, 52:259

treatment response, affective disorder, 52:259

treatment response, biogenic amines in plasma, 52:259

treatment response, moclobemide, 52:259

**Mood**

age, bereavement, 51:33

age, circadian rhythm, 51:33

age, depressive symptoms, 51:33

age, life events, 51:33

antidepressants, circadian rhythms, 52:85

antidepressants, motor activity, 52:85

antidepressants, treatment outcome, 52:85

attention, dichotic listening, 51:127

attention, electromyography, 51:127

attention, facial expression, 51:127

bereavement, age, 51:33

bereavement, circadian rhythm, 51:33

bereavement, depressive symptoms, 51:33

bereavement, life events, 51:33

cerebral blood flow, emotional discrimination task, 52:215

circadian rhythm, age, 51:33

circadian rhythm, bereavement, 51:33

circadian rhythm, depressive symptoms, 51:33

circadian rhythm, life events, 51:33

circadian rhythms, antidepressants, 52:85

circadian rhythms, motor activity, 52:85

circadian rhythms, treatment outcome, 52:85

circannual rhythms, eating disorder, 52:71

circannual rhythms, latitude, 52:71

circannual rhythms, seasonal affective disorder, 52:71

cortisol, epidural anesthesia, 54:241

cortisol, postpartum dysphoria, 54:241

depressive symptoms, age, 51:33

depressive symptoms, bereavement, 51:33

depressive symptoms, circadian rhythm, 51:33

depressive symptoms, gender, 53:259

**Mood** continued

depressive symptoms, Japanese and American adolescents, 53:259  
 depressive symptoms, life events, 51:33  
 depressive symptoms, response bias, 53:259  
 dichotic listening, attention, 51:127  
 dichotic listening, facial expression, 51:127  
 eating disorder, circannual rhythms, 52:71  
 eating disorder, seasonal affective disorder, 52:71  
 electromyography, attention, 51:127  
 electromyography, facial expression, 51:127  
 emotion-induction procedure, facial expression, 51:19  
 emotional discrimination task, cerebral blood flow, 52:215  
 epidural anesthesia, cortisol, 54:241  
 epidural anesthesia, postpartum dysphoria, 54:241  
 facial expression, emotion-induction procedure, 51:19  
 facial expression rating, schizophrenia, 54:211  
 facial expression rating, vocal acoustic analysis, 54:211  
 facial expression, attention, 51:127  
 facial expression, dichotic listening, 51:127  
 facial expression, electromyography, 51:127  
 gender, depressive symptoms, 53:259  
 gender, Japanese and American adolescents, 53:259  
 Japanese and American adolescents, depressive symptoms, 53:259  
 Japanese and American adolescents, depressive symptoms, 53:259  
 Japanese and American adolescents, gender, 53:259  
 Japanese and American adolescents, response bias, 53:259  
 latitude, circannual rhythms, 52:71  
 latitude, eating disorder, 52:71  
 latitude, seasonal affective disorder, 52:71  
 life events, age, 51:33  
 life events, bereavement, 51:33  
 life events, circadian rhythm, 51:33  
 life events, depressive symptoms, 51:33  
 motor activity, antidepressants, 52:85  
 motor activity, circadian rhythms, 52:85  
 motor activity, treatment outcome, 52:85  
 pictorial instrument for psychopathology assessment, children, 51:87  
 postpartum dysphoria, cortisol, 54:241  
 postpartum dysphoria, epidural anesthesia, 54:241  
 response bias, depressive symptoms, 53:259  
 response bias, Japanese and American adolescents, 53:259

**Mood** continued

schizophrenia, facial expression rating, 54:211  
 schizophrenia, vocal acoustic analysis, 54:211  
 seasonal affective disorder, circannual rhythms, 52:71  
 seasonal affective disorder, eating disorder, 52:71  
 seasonal affective disorder, latitude, 52:71  
 treatment outcome, antidepressants, 52:85  
 treatment outcome, circadian rhythms, 52:85  
 treatment outcome, motor activity, 52:85  
 vocal acoustic analysis, facial expression rating, 54:211  
 vocal acoustic analysis, schizophrenia, 54:211

**Motor activity**

antidepressants, circadian rhythms, 52:85  
 antidepressants, mood, 52:85  
 antidepressants, treatment outcome, 52:85  
 circadian rhythms, antidepressants, 52:85  
 circadian rhythms, mood, 52:85  
 circadian rhythms, treatment outcome, 52:85  
 defecation bolus counts, haloperidol, 54:87  
 defecation bolus counts, rat, 54:87  
 haloperidol, defecation bolus counts, 54:87  
 haloperidol, rat, 54:87  
 mood, antidepressants, 52:85  
 mood, circadian rhythms, 52:85  
 mood, treatment outcome, 52:85  
 neuroleptics, schizophrenia, 54:71  
 neuroleptics, tardive dyskinesia, 54:71  
 rat, defecation bolus counts, 54:87  
 rat, haloperidol, 54:87  
 schizophrenia, neuroleptics, 54:71  
 schizophrenia, tardive dyskinesia, 54:71  
 tardive dyskinesia, neuroleptics, 54:71  
 tardive dyskinesia, schizophrenia, 54:71  
 treatment outcome, antidepressants, 52:85  
 treatment outcome, circadian rhythms, 52:85  
 treatment outcome, mood, 52:85

**Motor performance**

heart rate, marijuana, 51:115

**Neopterin**

affective disorder, tryptophan, 54:143  
 interferon secretion, affective disorder, 54:143  
 tryptophan, interferon secretion, 54:143

**Neuroleptics**

anticipatory saccades, schizophrenia, 54:185  
 anticipatory saccades, smooth pursuit eye tracking, 54:185

**Neuroleptics** continued

catecholamines in cerebrospinal fluid, schizophrenia, 52:237  
 eye movements, anticipatory saccades, 54:185  
 eye movements, schizophrenia, 54:185  
 eye movements, smooth pursuit tracking, 54:185  
 haloperidol in plasma, schizophrenia, 52:107  
 haloperidol in plasma, treatment response, 52:107  
 interleukin, age, 51:1  
 interleukin, duration of illness, 51:1  
 interleukin, schizophrenia, 51:1  
 kynureine pathway, metanephrine, 52:251  
 kynureine pathway, schizophrenia, 52:251  
 kynureine pathway, treatment response, 52:251  
 3-methoxy-4-hydroxyphenylethleneglycol, schizophrenia, 51:51  
 motor activity, schizophrenia, 54:71  
 motor activity, tardive dyskinesia, 54:71  
 schizophrenia, age, 51:1  
 schizophrenia, catecholamines in cerebrospinal fluid, 52:237  
 schizophrenia, duration of illness, 51:1  
 schizophrenia, eye movements, 54:185  
 schizophrenia, haloperidol in plasma, 52:107  
 schizophrenia, interleukin, 51:1  
 schizophrenia, kynureine pathway, 52:251  
 schizophrenia, metanephrine, 52:251  
 schizophrenia, 3-methoxy-4-hydroxyphenylethleneglycol, 51:51  
 schizophrenia, motor activity, 54:71  
 schizophrenia, smooth pursuit eye tracking, 54:185  
 schizophrenia, tardive dyskinesia, 54:71  
 schizophrenia, treatment response, 52:107, 52:251  
 smooth pursuit tracking, anticipatory saccades, 54:185  
 smooth pursuit tracking, schizophrenia, 54:185  
 tardive dyskinesia, motor activity, 54:71  
 tardive dyskinesia, schizophrenia, 54:71  
 treatment response, haloperidol in plasma, 52:107  
 treatment response, schizophrenia, 52:107

**Neuropsychological performance**

acquired immune deficiency syndrome, electroencephalography, 54:1  
 acquired immune deficiency syndrome, fronto-occipital coherence, 54:1  
 affective disorder, delayed vs. immediate recall, 51:231  
 affective disorder, intelligence, 51:231  
 affective disorder, memory, 51:231  
 attention deficit disorder, intelligence, 53:13  
 delayed vs. immediate recall, affective disorder, 51:231

**Neuropsychological performance** continued

electroencephalography, acquired immune deficiency syndrome, 54:1  
 electroencephalography, fronto-occipital coherence, 54:1  
 family history, frontal lobe tasks, 54:37  
 family history, schizophrenia, 54:37  
 frontal lobe tasks, family history, 54:37  
 frontal lobe tasks, genetics, 54:37  
 frontal lobe tasks, schizophrenia, 54:37  
 fronto-occipital coherence, acquired immune deficiency syndrome, 54:1  
 fronto-occipital coherence, electroencephalography, 54:1  
 genetics, frontal lobe tasks, 54:37  
 genetics, nonpsychotic relatives, 53:1  
 genetics, schizophrenia, 53:1, 54:37  
 genetics, schizotypal personality disorder, 53:1  
 intelligence, affective disorder, 51:231  
 intelligence, attention deficit disorder, 53:13  
 intelligence, delayed vs. immediate recall, 51:231  
 intelligence, memory, 51:231  
 marijuana, reaction time, 51:115  
 memory, affective disorder, 51:231  
 memory, delayed vs. immediate recall, 51:231  
 positive symptoms, factor analysis, 54:51  
 positive symptoms, intelligence, 54:51  
 positive symptoms, schizophrenia, 54:51  
 reaction time, marijuana, 51:115  
 schizophrenia, factor analysis, 54:51  
 schizophrenia, family history, 54:37  
 schizophrenia, frontal lobe tasks, 54:37  
 schizophrenia, genetics, 53:1, 54:37  
 schizophrenia, intelligence, 54:51  
 schizophrenia, nonpsychotic relatives, 53:1  
 schizophrenia, positive symptoms, 54:51  
 schizophrenia, schizotypal personality disorder, 53:1

schizophrenia, thought disorder, 52:265  
 schizotypal personality disorder, genetics, 53:1  
 schizotypal personality disorder, nonpsychotic relatives, 53:1  
 schizotypal personality disorder, schizophrenia, 53:1  
 thought disorder, schizophrenia, 52:265

**Normal control subjects**

heart rate, lactate infusion, 54:97  
 research methodology, recruitment criteria, 53:301

**Obsessive-compulsive disorder**

anxiety disorder, social phobia, 51:167  
 autistic disorder, serotonin in plasma, 52:25

**Obsessive-compulsive disorder** continued  
 childhood disorders, serotonin in plasma, 52:25  
 clomipramine, symptom severity, 51:203  
 clomipramine, treatment response, 51:203  
 personality disorder, anxiety disorder, 51:167  
 personality disorder, social phobia, 51:167  
 serotonin in plasma, autistic disorder, 52:25  
 social phobia, personality disorder, 51:167  
 symptom severity, clomipramine, 51:203  
 treatment response, clomipramine, 51:203  
 treatment response, symptom severity, 51:203

#### **Panic disorder**

alprazolam, interleukin-1, 54:135  
 alprazolam, symptom severity, 54:135  
 anxiety symptoms, carbon dioxide, 52:159  
 anxiety symptoms, hypothalamic-pituitary-adrenal axis, 54:115  
 anxiety symptoms, meta-chlorophenylpiperazine, 54:115  
 carbon dioxide, anxiety symptoms, 52:159  
 cortisol, meta-chlorophenylpiperazine, 54:115  
 growth hormone, meta-chlorophenylpiperazine, 54:115  
 growth hormone, serotonin, 54:115  
 hypothalamic-pituitary-adrenal axis, anxiety symptoms, 54:115  
 hypothalamic-pituitary-adrenal axis, meta-chlorophenylpiperazine, 54:115  
 interleukin-1, alprazolam, 54:135  
 interleukin-1, symptom severity, 54:135  
 meta-chlorophenylpiperazine, anxiety symptoms, 54:115  
 meta-chlorophenylpiperazine, cortisol, 54:115  
 meta-chlorophenylpiperazine, growth hormone, 54:115  
 meta-chlorophenylpiperazine, hypothalamic-pituitary-adrenal axis, 54:115  
 meta-chlorophenylpiperazine, serotonin, 54:115  
 serotonin, growth hormone, 54:115  
 serotonin, meta-chlorophenylpiperazine, 54:115  
 symptom severity, alprazolam, 54:135  
 symptom severity, interleukin-1, 54:135

#### **Paroxetine**

serotonin, affective disorder, 51:147  
 serotonin, antidepressants, 51:147  
 serotonin, bipolar depression, 51:147  
 serotonin, platelets, 51:147

#### **Personality disorder**

affective disorder, antidepressant therapy, 53:153  
 affective disorder, treatment response, 53:153

#### **Personality disorder** continued

antidepressant therapy, affective disorder, 53:153  
 antidepressant therapy, treatment response, 53:153  
 anxiety disorder, obsessive-compulsive disorder, 51:167  
 anxiety disorder, social phobia, 51:167  
 obsessive-compulsive disorder, anxiety disorder, 51:167  
 obsessive-compulsive disorder, social phobia, 51:167  
 social phobia, anxiety disorder, 51:167  
 social phobia, obsessive-compulsive disorder, 51:167  
 treatment response, affective disorder, 53:153  
 treatment response, antidepressant therapy, 53:153

#### **Phospholipase A2**

alpha-amino-3-methyl-isoxazole-4-propionate receptor, antidepressant treatment, 51:107  
 antidepressant treatment, hippocampus, 51:107  
 hippocampus, rat, 51:107  
 hippocampus, trimipramine, 51:107  
 trimipramine, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107

#### **Phototherapy**

meta-chlorophenylpiperazine, seasonal affective disorder, 52:181  
 seasonal affective disorder, serotonin, 52:181  
 serotonin, meta-chlorophenylpiperazine, 52:181

#### **Pictorial instrument for children**

affective disorder, children, 51:87  
 mood, children, 51:87

#### **Platelets**

adenosine triphosphate, schizophrenia, 54:13  
 affective disorder, antidepressants, 51:147  
 affective disorder, bipolar subtype, 51:147  
 affective disorder, paroxetine binding, 51:147  
 affective disorder, serotonin, 51:147  
 antidepressants, affective disorder, 51:147  
 antidepressants, bipolar subtype, 51:147  
 antidepressants, paroxetine binding, 51:147  
 antidepressants, serotonin, 51:147  
 anxiety symptoms, posttraumatic stress disorder, 53:99  
 anxiety symptoms, serotonin, 53:99  
 bipolar depression, paroxetine binding, 51:147  
 bipolar depression, serotonin, 51:147  
 paroxetine binding, affective disorder, 51:147  
 paroxetine binding, antidepressants, 51:147  
 paroxetine binding, bipolar depression, 51:147

**Platelets** continued

- paroxetine binding, serotonin, 51:147
- posttraumatic stress disorder, anxiety symptoms, 53:99
- posttraumatic stress disorder, serotonin, 53:99
- schizophrenia, adenosine triphosphate, 54:13
- serotonin, affective disorder, 51:147
- serotonin, antidepressants, 51:147
- serotonin, anxiety symptoms, 53:99
- serotonin, bipolar depression, 51:147
- serotonin, paroxetine binding, 51:147
- serotonin, posttraumatic stress disorder, 53:99

**Postpartum depression**

- cortisol, epidural anesthesia, 54:241
- cortisol, mood, 54:241
- epidural anesthesia, mood, 54:241
- mood, cortisol, 54:241

**Posttraumatic stress**

- affective disorder, East German refugees, 51:61, 51:75
- affective disorder, prolactin, 51:75
- affective disorder, triiodothyronine, 51:61
- East German refugees, stress, 51:61
- East German refugees, thyroid stimulating hormone, 51:61
- luteinizing hormone, affective disorder, 51:75
- luteinizing hormone, East German refugees, 51:75
- prolactin, affective disorder, 51:75
- prolactin, East German refugees, 51:75
- serotonin, anxiety symptoms, 53:99
- serotonin, platelets, 53:99
- stress, East German refugees, 51:61
- stress, thyroid stimulating hormone, 51:61
- testosterone, affective disorder, 51:75
- testosterone, East German refugees, 51:75
- thyroxine, migration, 51:61
- triiodothyronine, affective disorder, 51:61
- triiodothyronine, East German refugees, 51:61
- thyroid stimulating hormone, East German refugees, 51:61
- thyroid stimulating hormone, stress, 51:61

**Prolactin**

- affective disorder, East German refugees, 51:75
- affective disorder, posttraumatic stress disorder, 51:75
- apomorphine, growth hormone, 53:231
- apomorphine, placebo controls, 52:317
- apomorphine, positive symptoms, 53:231
- apomorphine, schizophrenia, 52:317, 53:231
- buspirone, schizophrenia, 52:317

**Prolactin** continued

- clonidine, schizophrenia, 53:231
- gender, meta-chlorophenylpiperazine, 54:115
- growth hormone, apomorphine, 53:231
- growth hormone, positive symptoms, 53:231
- growth hormone, schizophrenia, 53:231
- healthy men, meta-chlorophenylpiperazine, 53:219
- meta-chlorophenylpiperazine, gender, 54:115
- meta-chlorophenylpiperazine, healthy men, 53:219
- placebo controls, apomorphine, 52:317
- placebo controls, schizophrenia, 52:317
- positive symptoms, apomorphine, 53:231
- positive symptoms, growth hormone, 53:231
- positive symptoms, schizophrenia, 53:231
- schizophrenia, apomorphine, 52:317, 53:231
- schizophrenia, buspirone, 52:317
- schizophrenia, clonidine, 53:231
- schizophrenia, growth hormone, 53:231
- schizophrenia, placebo controls, 52:317
- schizophrenia, positive symptoms, 53:231

**Psychotherapy**

- affective disorder, antidepressants, 53:289
- affective disorder, circadian rhythms, 51:297
- affective disorder, client-therapist ethnic match, 53:289
- affective disorder, imipramine, 51:297
- affective disorder, temperature, 51:297
- affective disorder, treatment outcome, 53:289
- antidepressants, affective disorder, 53:289
- antidepressants, client-therapist ethnic match, 53:289
- antidepressants, treatment outcome, 53:289
- circadian rhythms, affective disorder, 51:297
- circadian rhythms, imipramine, 51:297
- circadian rhythms, temperature, 51:297
- client-therapist ethnic match, affective disorder, 53:289
- client-therapist ethnic match, antidepressants, 53:289
- client-therapist ethnic match, treatment outcome, 53:289
- imipramine, affective disorder, 51:297
- imipramine, circadian rhythms, 51:297
- imipramine, temperature, 51:297
- temperature, affective disorder, 51:297
- temperature, circadian rhythms, 51:297
- temperature, imipramine, 51:297
- treatment outcome, affective disorder, 53:289
- treatment outcome, antidepressants, 53:289
- treatment outcome, client-therapist ethnic match, 53:289

**Putamen**

age, magnetic resonance imaging, 52:35  
 age, social phobia, 52:35  
 epilepsy, magnetic resonance imaging, 54:295  
 epilepsy, stereological sampling, 54:295  
 epilepsy, temporal lobe, 54:295  
 intelligence, schizophrenia, 53:243  
 magnetic resonance imaging, age, 52:35  
 magnetic resonance imaging, schizophrenia, 52:43, 54:25  
 magnetic resonance imaging, social phobia, 52:35  
 magnetic resonance imaging, epilepsy, 54:295  
 magnetic resonance imaging, stereological sampling, 54:295  
 magnetic resonance imaging, temporal lobe, 54:295  
 schizophrenia, intelligence, 53:243  
 schizophrenia, magnetic resonance imaging, 52:43, 54:25  
 social phobia, age, 52:35  
 social phobia, magnetic resonance imaging, 52:35  
 stereological sampling, epilepsy, 54:295  
 stereological sampling, magnetic resonance imaging, 54:295  
 stereological sampling, temporal lobe, 54:295  
 temporal lobe, epilepsy, 54:295  
 temporal lobe, magnetic resonance imaging, 54:295  
 temporal lobe, stereological sampling, 54:295

**Rat**

alpha-amino-3-methyl-isoxazole-4-propionate receptor, antidepressant treatment, 51:107  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, hippocampus, 51:107  
 alpha-amino-3-methyl-isoxazole-4-propionate receptor, phospholipase A2, 51:107  
 antidepressant treatment, hippocampus, 51:107  
 antidepressant treatment, phospholipase A2, 51:107  
 antidepressant treatment, trimipramine, 51:107  
 defecation bolus counts, haloperidol, 54:87  
 defecation bolus counts, motoractivity, 54:87  
 frontal lobe, microdialysis, 52:285  
 frontal lobe, serotonin, 52:285  
 haloperidol, defecation bolus counts, 54:87  
 haloperidol, motor activity, 54:87  
 hippocampus, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 hippocampus, antidepressant treatment, 51:107  
 hippocampus, phospholipase A2, 51:107  
 hippocampus, trimipramine, 51:107  
 learned helplessness, serotonin, 52:285  
 learned helplessness, stress, 52:285  
 learned helplessness, tail shock, 52:285

**Rat continued**

motor activity, defecation bolus counts, 54:87  
 motor activity, haloperidol, 54:87  
 phospholipase A2, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 phospholipase A2, antidepressant treatment, 51:107  
 phospholipase A2, hippocampus, 51:107  
 phospholipase A2, trimipramine, 51:107  
 serotonin, frontal lobe, 52:285  
 serotonin, learned helplessness, 52:285  
 serotonin, stress, 52:285  
 serotonin, tail shock, 52:285  
 stress, learned helplessness, 52:285  
 stress, serotonin, 52:285  
 stress, tail shock, 52:285  
 tail shock, learned helplessness, 52:285  
 tail shock, serotonin, 52:285  
 trimipramine, alpha-amino-3-methyl-isoxazole-4-propionate receptor, 51:107  
 trimipramine, hippocampus, 51:107  
 trimipramine, phospholipase A2, 51:107

**Reaction time**

marijuana, neuropsychology, 51:115

**Schizoaffective disorder**

dopamine D2 receptor gene linkage, schizophrenia, 53:203  
 3-methoxy-4-hydroxyphenylethleneglycol, plasma and cerebrospinal fluid, 51:51

**Schizophrenia**

adenosine triphosphate, platelet aggregation, 54:13  
 affective flattening, facial expression rating, 54:211  
 affective flattening, vocal acoustic analysis, 54:211  
 amino acids in plasma, psychotic symptoms, 51:11  
 amygdala size reduced, magnetic resonance imaging, 52:43  
 anticipatory saccades, neuroleptic treatment, 54:185  
 anticipatory saccades, smooth pursuit tracking, 54:185  
 apomorphine, growth hormone, 53:231  
 apomorphine, placebo controls, 52:317  
 apomorphine, positive symptoms, 53:231  
 apomorphine, prolactin, 52:317, 53:231  
 arachidonic acid platelet aggregation response, collagen, 54:13  
 ascorbic acid, cerebrospinal fluid, 52:237  
 attention, continuous performance test, 53:119, 54:259  
 attention, dermatoglyphics, 53:119

**Schizophrenia** continued

- attention, memory, 53:141
- attention, minor physical anomalies, 53:119
- attention, negative symptoms, 54:59
- attention, one-year outcome, 54:59
- attention, second trimester development, 53:119
- attention, siblings, 54:259
- attention, social cue perception, 53:141
- attention, social skills training, 53:141
- attention, symptom severity, 53:129
- attention, visual distractibility, 53:129
- autoantibodies, cytokines, 51:1
- brain size, gender, 53:243
- brain size, intelligence, 53:243
- brain size, magnetic resonance imaging, 53:243
- brain size, symptom severity, 53:243
- buspirone, prolactin response, 52:317
- catecholamines in cerebrospinal fluid, neuroleptic effects, 52:237
- cell adhesion, fibroblasts, 53:87
- cerebral blood flow, drug-naïve patients, 53:57
- cerebral blood flow, frontal lobe, 53:57
- cerebrospinal fluid, ascorbic acid, 52:237
- cerebrospinal fluid, epinephrine, 52:237
- cerebrospinal fluid, homovanillic acid, 52:237
- cerebrospinal fluid, 5-hydroxyindoleacetic acid, 52:237
- cerebrospinal fluid, kynurenone, 52:237
- cerebrospinal fluid, metanephrine, 52:237
- cerebrospinal fluid, 3-methoxy-4-hydroxyphenylethleneglycol, 52:237
- cerebrospinal fluid, serotonin, 52:237
- cerebrospinal fluid, tryptophan, 52:237
- cerebrospinal fluid, uric acid, 52:237
- cerebrospinal fluid, xanthine, 52:237
- clonidine, growth hormone response, 53:231
- clonidine, paranoid subtype, 53:231
- clonidine, prolactin, 53:231
- collagen, arachidonic acid platelet aggregation response, 54:13
- computed tomography, cortical atrophy, 53:41
- computed tomography, gender, 53:41
- computed tomography, genetics, 53:41
- computed tomography, ventricle-brain ratio, 53:41
- continuous performance test, attention, 53:119, 54:259
- continuous performance test, dermatoglyphics, 53:119
- continuous performance test, minor physical anomalies, 53:119
- continuous performance test, second trimester development, 53:119
- continuous performance test, siblings, 54:259

**Schizophrenia** continued

- cortical atrophy, computed tomography, 53:41
- cortical atrophy, gender, 53:41
- cortical atrophy, genetics, 53:41
- cortical atrophy, ventricle-brain ratio, 53:41
- cytokine, autoantibodies, 51:1
- dermatoglyphics, attention, 53:119
- dermatoglyphics, Continuous Performance Test, 53:119
- dermatoglyphics, minor physical anomalies, 53:119
- dermatoglyphics, second trimester development, 53:119
- dihydroxyphenylacetic acid, symptom severity, 52:251
- dopamine, D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215
- dopamine, D<sub>2</sub> receptor gene, 53:203
- dopamine, D<sub>4</sub> receptor gene, 53:77
- dopamine, genetics, 51:215, 53:77
- dopamine, linkage analysis, 51:215, 53:77, 53:203
- dopamine transporter gene, genetics, 52:17
- dopamine transporter gene, tandem repeats, 52:17
- epinephrine, cerebrospinal fluid, 52:237
- executive functions, frontal lobe, 52:265
- expressed emotion, Present State Examination, 54:273
- eye movements, anticipatory saccades, 54:185
- eye movements, neuroleptic treatment, 54:185
- eye movements, smooth pursuit tracking, 54:185
- facial expression rating, affective flattening, 54:211
- facial expression rating, vocal acoustic analysis, 54:211
- factor analysis, negative symptoms, 52:173, 52:295, 53:31
- factor analysis, positive symptoms, 52:295
- familial and sporadic cases, genetics, 54:25
- familial and sporadic cases, laterality, 54:25
- familial and sporadic cases, magnetic resonance imaging, 54:25
- familial and sporadic cases, ventricular size, 54:25
- familial risk, sex differences, 52:125
- family history, frontal lobe tasks, 54:37
- family history, neuropsychological performance, 54:37
- fibroblasts, cell adhesion, 53:87
- fibroectin, skin fibroblasts, 53:87
- frontal lobe, cerebral blood flow, 53:57
- frontal lobe, drug-naïve patients, 53:57
- frontal lobe, executive functions, 52:265
- frontal lobe tasks, family history, 54:37
- frontal lobe tasks, genetics, 54:37
- gender, brain size, 53:243
- gender, computed tomography, 53:41
- gender, cortical atrophy, 53:41

**Schizophrenia** continued

gender, genetics, 52:125, 53:41  
 gender, intelligence, 53:243  
 gender, lifetime risk of affective disorder, 52:125  
 gender, magnetic resonance imaging, 53:243  
 gender, symptom severity, 53:243  
 gender, ventricle-brain ratio, 53:41  
 genetics, computed tomography, 53:41  
 genetics, cortical atrophy, 53:41  
 genetics, dopamine D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 genetics, dopamine D<sub>4</sub> receptor gene, 53:77  
 genetics, dopamine transporter gene (DAT1), 52:17  
 genetics, familial and sporadic cases, 54:25  
 genetics, family history, 54:37  
 genetics, frontal lobe tasks, 54:37  
 genetics, gender, 52:125, 53:41  
 genetics, laterality, 54:25  
 genetics, lifetime risk of affective disorder, 52:125  
 genetics, linkage analysis, 51:215, 52:135, 53:77  
 genetics, magnetic resonance imaging, 54:25  
 genetics, neuropsychological performance, 53:1, 54:37  
 genetics, pseudoautosomal locus DXYS14, 52:135  
 genetics, schizotypal personality disorder, 53:1  
 genetics, tandem repeats, 52:17  
 genetics, ventricular size, 53:41, 54:25  
 growth hormone, apomorphine, 53:231  
 growth hormone, positive symptoms, 53:231  
 growth hormone, prolactin, 53:231  
 growth hormone, response to clonidine, negative symptoms, 53:231  
 growth hormone response, paranoid subtype, 53:231  
 haloperidol in plasma, neuroleptics, 52:107  
 haloperidol in plasma, treatment response, 52:107  
 haloperidol treatment, platelet aggregation, 54:13  
 homovanillic acid, cerebrospinal fluid, 52:237  
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 52:237  
 intelligence, brain size, 53:243  
 intelligence, gender, 53:243  
 intelligence, magnetic resonance imaging, 53:243  
 intelligence, nonpsychotic relatives, 53:1  
 intelligence, putamen size, 53:243  
 intelligence, symptom severity, 53:243  
 interleukin, age, 51:1  
 interleukin, duration of illness, 51:1  
 interleukin, neuroleptics, 51:1  
 kynurenone, cerebrospinal fluid, 52:237  
 kynurenone pathway, metanephrine, 52:251  
 kynurenone pathway, neuroleptics, 52:251

**Schizophrenia** continued

kynurenone pathway, treatment response, 52:251  
 laterality, familial and sporadic cases, 54:25  
 laterality, genetics, 54:25  
 laterality, magnetic resonance imaging, 54:25  
 laterality, ventricular size, 54:25  
 lifetime risk of affective disorder, gender, 52:125  
 lifetime risk of affective disorder, genetics, 52:125  
 linkage analysis, dopamine D<sub>1</sub>, D<sub>2</sub>, and D<sub>4</sub> receptor genes, 51:215  
 linkage analysis, dopamine D<sub>2</sub> receptor gene, 53:203  
 linkage analysis, dopamine D<sub>4</sub> receptor gene, 53:77  
 linkage analysis, pseudoautosomal locus DXYS14, 52:135  
 magnetic resonance imaging, amygdala size reduced, 52:43  
 magnetic resonance imaging, putamen, 52:43, 54:25  
 magnetic resonance imaging, temporal lobe, 52:43  
 magnetic resonance imaging, brain size, 53:243  
 magnetic resonance imaging, familial and sporadic cases, 54:25  
 magnetic resonance imaging, gender, 53:243  
 magnetic resonance imaging, genetics, 54:25  
 magnetic resonance imaging, intelligence, 53:243  
 magnetic resonance imaging, laterality, 54:25  
 magnetic resonance imaging, symptom severity, 53:243  
 magnetic resonance imaging, ventricular size, 54:25  
 memory, attention, 53:141  
 memory, social cue perception, 53:141  
 memory, social skills training, 53:141  
 metanephrine, cerebrospinal fluid, 52:237  
 methionine, serine challenge, 51:11  
 3-methoxy-4-hydroxyphenylethleneglycol, neuroleptic treatment, 51:51  
 3-methoxy-4-hydroxyphenylethleneglycol, cerebrospinal fluid, 52:237  
 minor physical anomalies, attention, 53:119  
 minor physical anomalies, continuous performance test, 53:119  
 minor physical anomalies, dermatoglyphics, 53:119  
 minor physical anomalies, second trimester development, 53:119  
 motor activity, neuroleptics, 54:71  
 motor activity, tardive dyskinesia, 54:71  
 negative symptoms, attention, 54:59  
 negative symptoms, factor analysis, 52:173, 52:295, 53:31  
 negative symptoms, growth hormone response to clonidine, 53:231  
 negative symptoms, one-year outcome, 54:59

**Schizophrenia** continued

- neuroleptic effects, catecholamines in cerebrospinal fluid, 52:237
- neuroleptic treatment, anticipatory saccades, 54:185
- neuroleptic treatment, eye movements, 54:185
- neuroleptic treatment, 3-methoxy-4-hydroxyphenylethleneglycol, 51:51
- neuroleptic treatment, smooth pursuit eye tracking, 54:185
- neuroleptics, haloperidol in plasma, 52:107
- neuroleptics, kynuremine pathway, 52:251
- neuroleptics, metanephrine, 52:251
- neuroleptics, motor activity, 54:71
- neuroleptics, tardive dyskinesia, 54:71
- neuroleptics, treatment response, 52:107, 52:251
- neuropsychological performance, factor analysis, 54:51
- neuropsychological performance, family history, 54:37
- neuropsychological performance, frontal lobe tasks, 54:37
- neuropsychological performance, genetics, 53:1, 54:37
- neuropsychological performance, intelligence, 54:51
- neuropsychological tests, nonpsychotic relatives, 53:1
- neuropsychological performance, positive symptoms, 54:51
- neuropsychological tests, schizotypal personality disorder, 53:1
- neuropsychological performance, thought disorder, 52:265
- nonpsychotic relatives, intelligence, 53:1
- outcome at 1 year, attention, 54:59
- outcome at 1 year, negative symptoms, 54:59
- outcome prediction, symptom severity, 52:107
- paranoid subtype, clonidine, 53:231
- paranoid subtype, growth hormone response, 53:231
- placebo controls, apomorphine, 52:317
- placebo controls, prolactin, 52:317
- platelet aggregation, haloperidol treatment, 54:13
- positive symptoms, apomorphine, 53:231
- positive symptoms, factor analysis, 52:295, 54:51
- positive symptoms, growth hormone, 53:231
- positive symptoms, intelligence, 54:51
- positive symptoms, neuropsychological performance, 54:51
- positive symptoms, prolactin, 53:231
- positive symptoms, scale reliability, 53:31
- Present State Examination, expressed emotion, 54:273

**Schizophrenia** continued

- prolactin, apomorphine, 52:317, 53:231
- prolactin, buspirone, 52:317
- prolactin, clonidine, 53:231
- prolactin, growth hormone, 53:231
- prolactin, placebo controls, 52:317
- prolactin, positive symptoms, 53:231
- pseudoautosomal locus DXYS14, genetics, 52:135
- pseudoautosomal locus DXYS14, linkage analysis, 52:135
- psychotic symptoms, amino acids in plasma, 51:11
- putamen, magnetic resonance imaging, 52:43, 54:25
- putamen size, intelligence, 53:243
- relapse criteria, symptom severity, 54:273
- relapse criteria, treatment outcome, 54:273
- scale reliability, positive symptoms, 53:31
- schizotypal personality disorder, genetics, 53:1
- schizotypal personality disorder, neuro-psychological tests, 53:1
- schizotypal personality disorder, nonpsychotic relatives, 53:1
- second trimester development, attention, 53:119
- second trimester development, continuous performance test, 53:119
- second trimester development, dermatoglyphics, 53:119
- second trimester development, minor physical anomalies, 53:119
- serine challenge, methionine, 51:11
- serine, taurine/serine plasma ratio, 51:11
- serotonin, cerebrospinal fluid, 52:237
- sex differences, familial risk, 52:125
- siblings, attention, 54:259
- siblings, continuous performance test, 54:259
- skin fibroblasts, fibroectin, 53:87
- smooth pursuit eye tracking, anticipatory saccades, 54:185
- smooth pursuit eye tracking, neuroleptic treatment, 54:185
- social cue perception, attention, 53:141
- social cue perception, memory, 53:141
- social cue perception, social skills training, 53:141
- social skills training, attention, 53:141
- social skills training, memory, 53:141
- social skills training, social cue perception, 53:141
- symptom severity, attention, 53:129
- symptom severity, brain size, 53:243
- symptom severity, dihydroxyphenylacetic acid, 52:251
- symptom severity, gender, 53:243
- symptom severity, intelligence, 53:243
- symptom severity, magnetic resonance imaging, 53:243

**Schizophrenia** continued

symptom severity, outcome prediction, 52:107  
 symptom severity, relapse criteria, 54:273  
 symptom severity, treatment outcome, 54:273  
 symptom severity, visual distractibility, 53:129  
 tandem repeats, dopamine transporter gene, 52:17  
 tandem repeats, genetics, 52:17  
 tardive dyskinesia, motor activity, 54:71  
 tardive dyskinesia, neuroleptics, 54:71  
 taurine/serine plasma ratio, serine, 51:11  
 temporal lobe, magnetic resonance imaging, 52:43  
 third ventricle, ventricle-brain ratio, 52:43  
 thought disorder, neuropsychological performance, 52:265  
 treatment outcome, relapse criteria, 54:273  
 treatment outcome, symptom severity, 54:273  
 treatment response, haloperidol in plasma, 52:107  
 treatment response, neuroleptics, 52:107  
 tryptophan, cerebrospinal fluid, 52:237  
 uric acid, cerebrospinal fluid, 52:237  
 ventricle-brain ratio, computed tomography, 53:41  
 ventricle-brain ratio, cortical atrophy, 53:41  
 ventricle-brain ratio, gender, 53:41  
 ventricle-brain ratio, genetics, 53:41  
 ventricle-brain ratio, third ventricle, 52:43  
 ventricular size, familial and sporadic cases, 54:25  
 ventricular size, genetics, 54:25  
 ventricular size, laterality, 54:25  
 ventricular size, magnetic resonance imaging, 54:25  
 visual distractibility, attention, 53:129  
 visual distractibility, symptom severity, 53:129  
 vocal acoustic analysis, affective flattening, 54:211  
 vocal acoustic analysis, facial expression rating, 54:211  
 xanthine, cerebrospinal fluid, 52:237

**Schizotypal personality disorder**

neuropsychological performance, nonpsychotic relatives, 53:1

**Seasonal affective disorder**

circannual rhythms, eating disorder, 52:71  
 circannual rhythms, latitude, 52:71  
 circannual rhythms, mood, 52:71  
 circannual rhythms, postexercise heat loss, 52:199  
 circannual rhythms, temperature regulation, 52:199  
 eating disorder, circannual rhythms, 52:71  
 eating disorder, latitude, 52:71  
 eating disorder, mood, 52:71  
 latitude, circannual rhythms, 52:71  
 latitude, eating disorder, 52:71  
 latitude, mood, 52:71

**Seasonal affective disorder** continued

meta-chlorophenylpiperazine, phototherapy, 52:181  
 meta-chlorophenylpiperazine, serotonin, 52:181  
 mood, circannual rhythms, 52:71  
 mood, eating disorder, 52:71  
 mood, latitude, 52:71  
 phototherapy, meta-chlorophenylpiperazine, 52:181  
 phototherapy, serotonin, 52:181  
 postexercise heat loss, circannual rhythms, 52:199  
 postexercise heat loss, temperature regulation, 52:199  
 serotonin, meta-chlorophenylpiperazine, 52:181  
 serotonin, phototherapy, 52:181  
 temperature regulation, circannual rhythms, 52:199  
 temperature regulation, postexercise heat loss, 52:199

**Serine**

affective disorder, methionine, 51:11  
 methionine, plasma levels, 51:11  
 schizophrenia, taurine/serine plasma ratio, 51:11  
 taurine, affective disorder, 51:11  
 taurine, methionine, 51:11

**Serotonin**

autistic disorder, childhood disorders, 52:25  
 autistic disorder, obsessive-compulsive symptoms, 52:25  
 childhood disorders, autistic disorder, 52:25  
 childhood disorders, obsessive-compulsive symptoms, 52:25  
 depressed mood, Down's syndrome, 52:25  
 depressed mood, genetics, 52:25  
 Down's syndrome, depressed mood, 52:25  
 Down's syndrome, genetics, 52:25  
 frontal lobe, microdialysis, 52:285  
 frontal lobe, rat, 52:285  
 genetics, depressed mood, 52:25  
 genetics, Down's syndrome, 52:25  
 growth hormone, meta-chlorophenylpiperazine, 54:115  
 growth hormone, panic disorder, 54:115  
 learned helplessness, rat, 52:285  
 learned helplessness, stress, 52:285  
 learned helplessness, tail shock, 52:285  
 meta-chlorophenylpiperazine, growth hormone, 54:115  
 meta-chlorophenylpiperazine, panic disorder, 54:115  
 meta-chlorophenylpiperazine, phototherapy, 52:181  
 meta-chlorophenylpiperazine, seasonal affective disorder, 52:181  
 obsessive-compulsive symptoms, autistic disorder, 52:25

**Serotonin** continued

obsessive-compulsive symptoms, childhood disorders, 52:25  
 panic disorder, growth hormone, 54:115  
 panic disorder, meta-chlorophenylpiperazine, 54:115  
 paroxetine binding, affective disorder, 51:147  
 paroxetine binding, antidepressants, 51:147  
 paroxetine binding, bipolar subtype, 51:147  
 paroxetine binding, platelets, 51:147  
 phototherapy, meta-chlorophenylpiperazine, 52:181  
 phototherapy, seasonal affective disorder, 52:181  
 posttraumatic stress disorder, anxiety symptoms, 53:99  
 posttraumatic stress disorder, platelets, 53:99  
 rat, frontal lobe, 52:285  
 rat, learned helplessness, 52:285  
 rat, microdialysis, 52:285  
 rat, stress, 52:285  
 rat, tail shock, 52:285  
 schizophrenia, cerebrospinal fluid, 52:237  
 seasonal affective disorder, meta-chlorophenylpiperazine, 52:181  
 seasonal affective disorder, phototherapy, 52:181  
 stress, learned helplessness, 52:285  
 stress, rat, 52:285  
 stress, tail shock, 52:285  
 tail shock, learned helplessness, 52:285  
 tail shock, rat, 52:285  
 tail shock, stress, 52:285

**Sex differences.** See *Gender***Sleep**

affective disorder, antidepressants, 52:327  
 affective disorder, circadian temperature rhythm, 51:297  
 affective disorder, clomipramine, 54:161  
 affective disorder, desmethylclomipramine metabolite, 54:161  
 affective disorder, dream reports, 51:245  
 affective disorder, fluoxetine, 51:297, 52:327  
 affective disorder, 3-methoxy-4-hydroxyphenylethleneglycol, 51:157  
 affective disorder, rapid eye movement sleep latency, 51:245, 51:269, 52:327  
 affective disorder, rapid eye movement sleep rebound, 54:161  
 affective disorder, treatment-response prediction, 52:327  
 affective disorder, unipolar subtype, 51:157  
 antidepressant response, motor activity, 52:85  
 antidepressants, affective disorder, 52:327  
 antidepressants, fluoxetine, 52:327

**Sleep** continued

antidepressants, rapid eye movement sleep latency, 52:327  
 antidepressants, treatment response prediction, 52:327  
 cholinergic system, cholinesterase inhibitors, 51:253  
 cholinergic system, galanthamine, 51:253  
 cholinergic system, rapid eye movement sleep latency, 51:253  
 circadian temperature rhythm, affective disorder, 51:297  
 circadian temperature rhythm, fluoxetine, 51:297  
 clomipramine, affective disorder, 54:161  
 clomipramine, desmethylclomipramine metabolite, 54:161  
 clomipramine, rapid eye movement sleep rebound, 54:161  
 depression symptoms, affective disorder, 51:245  
 depression symptoms, dream reports, 51:245  
 depression symptoms, rapid eye movement sleep latency, 51:245  
 dream reports, affective disorder, 51:245  
 dream reports, depression symptoms, 51:245  
 dream reports, rapid eye movement sleep latency, 51:245  
 eating disorder, seasonal affective disorder, 52:71  
 fluoxetine, affective disorder, 51:297, 52:327  
 fluoxetine, circadian temperature rhythm, 51:297  
 fluoxetine, rapid eye movement sleep latency, 52:327  
 fluoxetine, treatment-response prediction, 52:327  
 galanthamine, cholinergic system, 51:253  
 galanthamine, cholinesterase inhibitors, 51:253  
 galanthamine, rapid eye movement sleep latency, 51:253  
 hours per night, eating disorder, 52:71  
 hours per night, seasonal affective disorder, 52:71  
 3-methoxy-4-hydroxyphenylethleneglycol, affective disorder, 51:157  
 3-methoxy-4-hydroxyphenylethleneglycol, unipolar depression, 51:157  
 motor activity, antidepressant response, 52:85  
 rapid eye movement sleep latency, affective disorder, 51:245, 52:327  
 rapid eye movement sleep latency, antidepressants, 52:327  
 rapid eye movement sleep latency, cholinergic system, 51:253  
 rapid eye movement sleep latency, cholinesterase inhibitors, 51:253  
 rapid eye movement sleep latency, depression symptoms, 51:245

**Sleep** continued

- rapid eye movement sleep latency, dream reports, 51:245
- rapid eye movement sleep latency, fluoxetine, 52:327
- rapid eye movement sleep latency, galanthamine, 51:253
- rapid eye movement sleep latency, treatment-response prediction, 52:327
- rapid eye movement sleep rebound, affective disorder, 54:161
- rapid eye movement sleep rebound, clomipramine, 54:161
- rapid eye movement sleep rebound, desmethylclomipramine metabolite, 54:161
- seasonal affective disorder, eating disorder, 52:71
- treatment-response prediction, affective disorder, 52:327
- treatment-response prediction, antidepressants, 52:327
- treatment-response prediction, fluoxetine, 52:327
- treatment-response prediction, rapid eye movement sleep latency, 52:327
- unipolar subtype, affective disorder, 51:157
- unipolar subtype, 3-methoxy-4-hydroxyphenylethleneglycol, 51:157

**Sleep deprivation**

- affective disorder, desmethylimipramine, 51:283
- affective disorder, lithium, 51:283
- affective disorder, thyroid hormones, 53:107
- affective disorder, treatment response, 51:283
- desipramine, affective disorder, 51:283
- desipramine, lithium, 51:283
- desipramine, treatment response, 51:283
- lithium, affective disorder, 51:283
- lithium, desmethylimipramine, 51:283
- lithium, treatment response, 51:283
- thyroid hormones, affective disorder, 53:107
- treatment response, affective disorder, 51:283
- treatment response, desmethylimipramine, 51:283
- treatment response, lithium, 51:283

**Social phobia**

- age, magnetic resonance imaging, 52:35
- age, putamen size, 52:35
- anxiety disorder, obsessive-compulsive disorder, 51:167
- anxiety disorder, personality disorder, 51:167
- anxiety symptoms, outcome analysis, 54:249
- anxiety symptoms, remission, 54:249
- attention deficit disorder, sex differences, 53:13
- magnetic resonance imaging, age, 52:35

**Social phobia** continued

- magnetic resonance imaging, putamen size, 52:35
- obsessive-compulsive disorder, anxiety disorder, 51:167
- obsessive-compulsive disorder, personality disorder, 51:167
- outcome analysis, anxiety symptoms, 54:249
- outcome analysis, remission, 54:249
- personality disorder, anxiety disorder, 51:167
- personality disorder, obsessive-compulsive disorder, 51:167
- point-counting, thalamus size, 52:35
- putamen size, age, 52:35
- putamen size, magnetic resonance imaging, 52:35
- remission, anxiety symptoms, 54:249
- remission, outcome analysis, 54:249
- sex differences, attention deficit disorder, 53:13
- thalamus size, point-counting, 52:35

**Social skills training**

- attention, memory, 53:141
- memory, schizophrenia, 53:141
- schizophrenia, social cue perception, 53:141
- social cue perception, attention, 53:141

**Statistics**

- factor analysis, schizophrenia negative symptoms, 52:173, 52:295, 53:31
- factor analysis, schizophrenia positive symptoms, 52:295
- intraclass correlation coefficient, proportion of variance due to traits, 52:43
- matched samples, paired *t*-test program available, 54:305
- multiple linear regression, state and trait variables, 52:43
- paired *t*-test program available, matched samples, 54:305
- proportion of variance due to traits, intraclass correlation coefficient, 52:43
- state and trait variables, multiple linear regression, 52:43

**Stress**

- learned helplessness, rat, 52:285
- learned helplessness, serotonin, 52:285
- learned helplessness, tail shock, 52:285
- posttraumatic stress disorder, East German refugees, 51:61
- posttraumatic stress disorder, thyroid stimulating hormone, 51:61
- rat, learned helplessness, 52:285
- rat, serotonin, 52:285

**Stress** continued

- rat, tail shock, 52:285
- serotonin, learned helplessness, 52:285
- tail shock, learned helplessness, 52:285
- tail shock, rat, 52:285
- thyroid stimulating hormone, posttraumatic stress disorder, 51:61

**Substance abuse**

- cannabinol use, homovanillic acid, 52:103
- adrenocorticotrophic hormone, cannabinol use, 52:103
- attention deficit disorder, sex differences, 53:13
- cannabinol use, adrenocorticotrophic hormone, 52:103
- cannabinol use, corticotropin releasing factor, 52:103
- cannabinol use, 5-hydroxyindoleacetic acid, 52:103
- cannabinol use, 3-methoxy-4-hydroxyphenylethleneglycol, 52:103
- corticotropin releasing factor, cannabinol use, 52:103
- homovanillic acid, cannabinol use, 52:103
- 5-hydroxyindoleacetic acid, cannabinol use, 52:103
- 3-methoxy-4-hydroxyphenylethleneglycol, cannabinol use, 52:103
- sex differences, attention deficit disorder, 53:13

**T-cells**

- affective disorder, bereavement, 52:1
- bereavement, immune function, 52:1
- immune function, lymphocyte counts, 52:1
- lymphocyte counts, natural killer cells, 52:1
- natural killer cells, affective disorder, 52:1

**Tardive dyskinesia**

- motor activity, neuroleptics, 54:71
- neuroleptics, schizophrenia, 54:71
- schizophrenia, motor activity, 54:71

**Taurine**

- affective disorder, methionine, 51:11
- methionine, plasma levels, 51:11
- serine, plasma levels, 51:11

**Temperature**

- affective disorder, circadian rhythms, 51:297
- affective disorder, imipramine, 51:297
- affective disorder, psychotherapy response, 51:297
- childhood disorders, circadian rhythms, 52:273
- childhood disorders, epilepsy, 52:273
- childhood disorders, melatonin, 52:273
- circadian rhythms, affective disorder, 51:297

**Temperature** continued

- circadian rhythms, childhood disorders, 52:273
- circadian rhythms, epilepsy, 52:273
- circadian rhythms, imipramine, 51:297
- circadian rhythms, melatonin, 52:273
- circadian rhythms, psychotherapy response, 51:297
- circannual rhythms, postexercise heat loss, 52:199
- circannual rhythms, seasonal affective disorder, 52:199
- epilepsy, childhood disorders, 52:273
- epilepsy, circadian rhythms, 52:273
- epilepsy, melatonin, 52:273
- imipramine, affective disorder, 51:297
- imipramine, circadian rhythms, 51:297
- imipramine, psychotherapy response, 51:297
- melatonin, childhood disorders, 52:273
- melatonin, circadian rhythms, 52:273
- melatonin, epilepsy, 52:273
- postexercise heat loss, circannual rhythms, 52:199
- postexercise heat loss, seasonal affective disorder, 52:199
- psychotherapy response, affective disorder, 51:297
- psychotherapy response, circadian rhythms, 51:297
- psychotherapy response, imipramine, 51:297
- seasonal affective disorder, circannual rhythms, 52:199
- seasonal affective disorder, postexercise heat loss, 52:199

**Temporal lobe**

- epilepsy, magnetic resonance imaging, 54:295
- epilepsy, putamen, 54:295
- epilepsy, stereological sampling, 54:295
- glucose metabolic rate, gender differences, 51:175
- intelligence, gender differences, 53:243
- magnetic resonance imaging, schizophrenia, 52:43
- magnetic resonance imaging, epilepsy, 54:295
- magnetic resonance imaging, putamen, 54:295
- magnetic resonance imaging, stereological sampling, 54:295
- magnetic resonance imaging, gender differences, 53:243
- positron emission tomography, gender differences, 51:175
- putamen, epilepsy, 54:295
- putamen, magnetic resonance imaging, 54:295
- putamen, stereological sampling, 54:295
- schizophrenia, magnetic resonance imaging, 52:43

**Testosterone**

- posttraumatic stress disorder, East German refugees, 51:75

**Thalamus**

affective disorder, electroconvulsive therapy, 54:177  
 affective disorder, magnetic resonance imaging, 54:177  
 affective disorder, memory, 54:177  
 electroconvulsive therapy, affective disorder, 54:177  
 electroconvulsive therapy, magnetic resonance imaging, 54:177  
 electroconvulsive therapy, memory, 54:177  
 magnetic resonance imaging, affective disorder, 54:177  
 magnetic resonance imaging, electroconvulsive therapy, 54:177  
 magnetic resonance imaging, memory, 54:177  
 memory, affective disorder, 54:177  
 memory, electroconvulsive therapy, 54:177  
 memory, magnetic resonance imaging, 54:177  
 point-counting, social phobia, 52:35  
 social phobia, point counting, 52:35

**Third ventricle**

schizophrenia, ventricle-brain ratio, 52:43

**Thyroid hormone**

affective disorder, dexamethasone, 51:185  
 affective disorder, East German refugees, 51:61  
 affective disorder, posttraumatic stress disorder, 51:61  
 dexamethasone, affective disorder, 51:185  
 posttraumatic stress disorder, affective disorder, 51:61  
 posttraumatic stress disorder, East German refugees, 51:61  
 sleep deprivation, affective disorder, 53:107

**Thyroid stimulating hormone**

affective disorder, melancholic subtype, 51:185  
 East German refugees, posttraumatic stress disorder, 51:61  
 East German refugees, stress, 51:61  
 melancholic subtype, affective disorder, 51:185  
 posttraumatic stress disorder, East German refugees, 51:61  
 posttraumatic stress disorder, stress, 51:61  
 stress, East German refugees, 51:61  
 stress, posttraumatic stress disorder, 51:61

**Trimipramine**

alpha-amino-3-methyl-isoxazole-4-propionate receptor, antidepressant treatment, 51:107  
 antidepressant treatment, hippocampus, 51:107  
 hippocampus, phospholipase A2, 51:107  
 phospholipase A2, rat, 51:107

**Tryptophan**

affective disorder, interferon secretion, 54:143

**Tryptophan** continued

affective disorder, neopterin, 54:143  
 cerebrospinal fluid, schizophrenia, 52:237  
 interferon secretion, affective disorder, 54:143  
 interferon secretion, neopterin, 54:143  
 neopterin, affective disorder, 54:143  
 neopterin, interferon secretion, 54:143

**Uric acid**

schizophrenia, cerebrospinal fluid, 52:237

**Ventricles**

computed tomography, cortical atrophy, 53:41  
 computed tomography, gender, 53:41  
 computed tomography, genetics, 53:41  
 computed tomography, schizophrenia, 53:41  
 cortical atrophy, computed tomography, 53:41  
 cortical atrophy, gender, 53:41  
 cortical atrophy, genetics, 53:41  
 cortical atrophy, schizophrenia, 53:41  
 gender, computed tomography, 53:41  
 gender, cortical atrophy, 53:41  
 gender, genetics, 53:41  
 gender, schizophrenia, 53:41  
 genetics, computed tomography, 53:41  
 genetics, cortical atrophy, 53:41  
 genetics, familial and sporadic cases, 54:25  
 genetics, gender, 53:41  
 genetics, laterality, 54:25  
 genetics, magnetic resonance imaging, 54:25  
 genetics, schizophrenia, 53:41, 54:25  
 laterality, familial and sporadic cases, 54:25  
 laterality, genetics, 54:25  
 laterality, magnetic resonance imaging, 54:25  
 laterality, schizophrenia, 54:25  
 magnetic resonance imaging, genetics, 54:25  
 magnetic resonance imaging, laterality, 54:25  
 magnetic resonance imaging, schizophrenia, 54:25  
 schizophrenia, computed tomography, 53:41  
 schizophrenia, cortical atrophy, 53:41  
 schizophrenia, familial and sporadic cases, 54:25  
 schizophrenia, gender, 53:41  
 schizophrenia, genetics, 53:41, 54:25  
 schizophrenia, laterality, 54:25  
 schizophrenia, magnetic resonance imaging, 54:25  
 schizophrenia, third ventricle, 52:43  
 third ventricle, schizophrenia, 52:43

**Xanthine**

schizophrenia, cerebrospinal fluid, 52:237